




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07D 401/00	A2	(11) International Publication Number: WO 99/55693 (43) International Publication Date: 4 November 1999 (04.11.99)
<p>(21) International Application Number: PCT/EP99/02815</p> <p>(22) International Filing Date: 26 April 1999 (26.04.99)</p> <p>(30) Priority Data: 959/98 28 April 1998 (28.04.98) CH</p> <p>(71) Applicant (for all designated States except AT US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).</p> <p>(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KUNZ, Walter [CH/CH]; Buchenstrasse 9, CH-4104 Oberwil (CH). NEBEL, Kurt [CH/CH]; Baselweg 32, CH-4146 Hochwald (CH).</p> <p>(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).</p>		<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published Without international search report and to be republished upon receipt of that report.</p>

(54) Title: NOVEL HERBICIDES



(57) Abstract

Compounds of formula (I), wherein A = N- or (a); R₁ is hydrogen, fluorine, chlorine, bromine or methyl; R₂ is C₁-C₄alkyl, C₁-C₄halogenalkyl, halogen, hydroxy, C₁-C₄alkoxy, C₁-C₄halogenalkoxy, nitro, amino or cyano; W is a (W1), (W2), (W3), (W4), (W5), (W6), (W7), (W8), (W9) or (W10) group; and R₃, R₁₅ to R₃₉ and X₆ to X₁₉ are as defined in claim 1, and the agrochemically acceptable salts and stereoisomers of these compounds of formula (I) are suitable for use as herbicides.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

Novel Herbicides

The present invention relates to new, herbicidally active, substituted n-pyridyl-nitrogen heterocycles, methods for the preparation thereof, compositions comprising these compounds, and the use thereof for weed control, especially in crops of cultivated plants, such as grain, cereals, maize, rice, cotton, soybeans, rape, sorghum, sugar cane, sugar beet, sunflowers, vegetables, plantations, and forage crops or for the inhibition of plant growth and for non-selective control of weeds.


N-Phenyl and N-pyridylpyrazole compounds and N-pyridyltetramethylenetriazolidinediones with a herbicidal action are described, for example, in EP-A-0 370 332, DE-A-3 917 469, DE-A-19 518 054, DE-A-19 530 606, US-A-5 306 694 and US-A-4 406 689.

Also known as herbicides are N-pyridylimides, N-(2-pyridyl)pyridazinones and 3-phenyluracils, as described for example in WO 92/00976, JP-A-58-213 776 and EP-A-0 438 209.


N-(Phenyl)tetrahydroimidazoles with a herbicidal action are described for example in US-A-5 112 383.

New substituted n-pyridyl-nitrogen heterocycles have now been found with herbicidal and growth-inhibiting properties.

Accordingly, the invention relates to compounds of formula I



wherein



R₁ is hydrogen, fluorine, chlorine, bromine or methyl;

R₂ is C₁-C₄alkyl, C₁-C₄halogenalkyl, halogen, hydroxy, C₁-C₄alkoxy, C₁-C₄halogenalkoxy, nitro, amino or cyano;

R₃ is cyano or R₄C(O)-;

R₄ is hydrogen, fluorine, chlorine, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₆cycloalkyl, C₁-C₈halogenalkyl, cyano-C₁-C₄alkyl, C₂-C₈halogenalkenyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl; or

R₃ is R₅X₁C(O)-;

X₁ is oxygen, sulfur, $\begin{array}{c} R_6-N- \\ | \end{array}$ or $\begin{array}{c} R_7-O-N- \\ | \end{array}$;

R₅ is hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₃-C₆cycloalkyl, C₃-C₆cycloalkyl-C₁-C₆alkyl, C₁-C₈halogenalkyl, C₃-C₈halogenalkenyl, cyano-C₁-C₄alkyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, (oxiranyl)-CH₂-, oxetanyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄-

halogenalkyl, phenyl-C₂-C₆alkyl, C₁-C₆alkyl-CO-C₁-C₄alkyl, $\begin{array}{c} C_1-C_6-Alkyl-C(O)-[C_1-C_4-alkylen]- \\ | \\ (C_6H_5) \end{array}$

, $\begin{array}{c} R_8X_2C(O)-[C_1-C_6-alkylen]- \\ | \\ (C_6H_5) \end{array}$ or R₈X₂C(O)-C₃-C₆cycloalkyl;

X₂ is oxygen, sulfur, $\begin{array}{c} R_9-N- \\ | \end{array}$ or $\begin{array}{c} R_{10}-O-N- \\ | \end{array}$;

R₈ is hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₃-C₆cycloalkyl, C₁-C₈halogenalkyl, C₃-C₈halogenalkenyl, cyano-C₁-C₄alkyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, (oxiranyl)-CH₂-, oxetanyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, or phenyl-C₂-C₆alkyl;

R₆, R₇, R₉ and R₁₀ are independently of one another hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₁-C₈halogenalkyl or benzyl; or

R₃ is B₁-C₁-C₈alkyl, B₁-C₂-C₈alkenyl, B₁-C₂-C₈alkinyl, B₁-C₁-C₈halogenalkyl, B₁-C₂-C₈halogenalkenyl, B₁-C₁-C₄alkoxy-C₁-C₄alkyl, B₁-C₁-C₄alkylthio-C₁-C₄alkyl or B₁-C₃-C₆cycloalkyl;

B₁ is hydrogen, cyano, hydroxy, C₁-C₈alkoxy, C₃-C₈alkenyloxy, R₁₁X₃C(O)-, C₁-C₄alkylcarbonyl or C₁-C₄halogenalkylcarbonyl ;

X₃ has the same meaning as X₂;

R_{11} has the same meaning as R_8 ; or


R_3 is $B_2-C(R_{12})=CH-$;

B_2 is nitro, cyano or $R_{13}X_4C(O)-$;

R_{12} is cyano or $R_{14}X_5C(O)-$;

X_4 and X_5 have the same meaning as X_2 ; and

R_{13} and R_{14} have the same meaning as R_8 ;



R_{15} is C_1 - C_3 alkyl, C_1 - C_3 halogenalkyl or amino;

R_{16} is C_1 - C_3 halogenalkyl, C_1 - C_3 alkyl- $S(O)_{n1}$, C_1 - C_3 halogenalkyl- $S(O)_{n1}$ or cyano; or

R_{16} and R_{15} together form a C_3 - or C_4 alkylene or C_3 - or C_4 alkenylene bridge which may be substituted by halogen, C_1 - C_3 halogenalkyl or cyano;

n_1 is 0, 1 or 2;

R_{17} is hydrogen, C_1 - C_3 alkyl, halogen, C_1 - C_3 halogenalkyl or cyano; or

R_{17} and R_{16} together form a C_3 - or C_4 alkylene or C_3 - or C_4 alkenylene bridge which may be substituted by halogen, C_1 - C_3 halogenalkyl or cyano;

R_{18} is hydrogen, C_1 - C_3 alkyl, halogen or cyano;

R_{19} is C_1 - C_3 halogenalkyl; or

R_{19} and R_{18} together form a C_3 - or C_4 alkylene or C_3 - or C_4 alkenylene bridge which may be substituted by halogen, C_1 - C_3 halogenalkyl or cyano;

R_{20} is hydrogen or C_1 - C_3 alkyl or halogen; or

R_{20} and R_{19} together form a C_3 - or C_4 alkylene or C_3 - or C_4 alkenylene bridge which may be substituted by halogen, C_1 - C_3 halogenalkyl or cyano;

R_{21} is hydrogen, C_1 - C_3 alkyl, halogen, C_1 - C_3 halogenalkyl, $R_{40}O$ -, $R_{41}S(O)_{n2}$, $R_{42}(R_{43})N$, $R_{45}(R_{46})N-C(R_{44})=N$ -, hydroxy, nitro or $N\equiv C-S$ - ;

R_{40} is C_1 - C_3 alkyl, C_1 - C_3 halogenalkyl, C_2 - C_4 alkenyl, C_3 - or C_4 alkinyl or C_1 - C_5 alkoxycarbonyl- C_1 - C_4 alkyl;

R_{41} is C_1 - C_4 alkyl or C_1 - C_4 halogenalkyl;

n_2 is 0, 1 or 2;

R_{42} is hydrogen, C_1 - C_4 alkyl, C_1 - C_4 halogenalkyl, C_3 - C_6 cycloalkyl, OHC - or C_1 - C_4 alkylcarbonyl;

R_{43} , R_{44} , and R_{46} are independently of one another hydrogen or C_1 - C_4 alkyl;

R_{45} is C_1 - C_4 alkyl;

R_{22} is hydrogen, C_1 - C_4 alkyl, halogen, C_1 - C_4 halogenalkyl, C_2 - C_4 alkenyl, C_3 - C_5 halogenalkenyl, C_3 - or C_4 alkinyl, C_1 - C_4 alkoxy, C_1 - C_4 alkylcarbonyl, C_1 - C_4 halogenalkylcarbonyl, C_2 - C_4 alkenylcarbonyl, C_2 - C_4 halogenalkenylcarbonyl, C_2 - C_4 alkinylcarbonyl, C_2 - C_4 halogenalkinylcarbonyl, C_1 - C_4 alkylcarbonyl, C_1 - C_4 alkylS(O) $_{n3}$, C_3 - or C_4 alkinylS(O) $_{n3}$, OHC -, nitro, amino, cyano or $N\equiv C-S$ - ;

n_3 is 0, 1 or 2;

R_{23} and R_{24} independently of one another are hydrogen, C_1 - C_4 alkyl, halogen, C_1 - C_4 halogenalkyl or cyano;

R_{25} and R_{26} are independently of one another hydrogen, methyl, halogen, hydroxy or $=O$;

R_{27} and R_{28} are independently of one another hydrogen, C_1 - C_4 alkyl or C_1 - C_4 halogenalkyl;

R_{29} and R_{30} are independently of one another hydrogen, C_1 - C_3 alkyl or halogen;

R_{31} and R_{32} independently of one another are hydrogen or C_1 - C_4 alkyl; or

R_{31} and R_{32} together form the group $\begin{array}{c} R_{47} \\ \diagup \\ =C \\ \diagdown \\ R_{48} \end{array}$;

R_{47} and R_{48} are independently of one another C_1 - C_4 alkyl; or

R_{47} and R_{48} together form a C_4 or C_5 alkylene bridge;

R_{33} is hydrogen or C_1 - C_3 alkyl; or

R_{33} together with R_{32} forms a C_3 - C_5 alkylene bridge which may be broken by oxygen and/or substituted by halogen, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_1 - C_3 alkylcarbonyloxy, C_1 - C_3 alkylsulfonyloxy, hydroxy or $=O$;

R_{34} , R_{35} , R_{36} and R_{37} are independently of one another hydrogen, C_1 - C_3 alkyl, C_3 - or C_4 alkenyl or C_3 - C_5 alkinyl; or

R_{34} and R_{35} on the one hand and R_{36} and R_{37} on the other each form a C_2 - C_5 alkylene or C_3 - C_5 alkenylene bridge, which may be broken by oxygen, $-C(O)-$, sulfur, or $-S(O)_2-$;
 R_{38} is hydrogen, C_1 - C_4 alkyl, C_1 - C_4 halogenalkyl, C_3 - or C_4 alkenyl or C_3 - or C_4 alkinyl;
 R_{39} is hydrogen, C_1 - C_4 alkyl, C_1 - C_3 alkoxy- C_1 - or $-C_2$ alkyl, C_1 - C_4 halogenalkyl, C_3 - or C_4 alkenyl, C_3 - or C_4 halogenalkenyl or C_3 - or C_4 alkinyl; or
 R_{39} and R_{38} together form a C_3 - C_5 alkylene bridge; and
 X_6 , X_7 , X_8 , X_9 , X_{10} , X_{11} , X_{12} , X_{13} , X_{14} , X_{15} , X_{16} , X_{17} , X_{18} and X_{19} are independently of one another oxygen or sulfur,
and the agrochemically acceptable salts and stereoisomers of these compounds of formula I.

In the definitions listed hereinbefore, halogen is taken to mean iodine, preferably fluorine, chlorine and bromine.

The alkyl, alkenyl and alkinyl groups mentioned in the substituent definitions may be straight-chained or branched, as is also the case with the alkyl, alkenyl and alkinyl part of the alkylcarbonyl, alkylcarbonyloxy, alkylcarbonylalkyl, alkenyloxy, alkenyloxyalkyl, alkenylcarbonyl, alkinylcarbonyl, alkylcarbonyl, hydroxyalkyl, cyanoalkyl, alkoxyalkyl, alkylthio, alkylthioalkyl, alkylthio- $C(O)-$, alkyl $S(O)_n$, alkylsulfonyloxy, alkylaminocarbonyl, dialkylaminocarbonyl, alkylcarbonylalkyl, B_1 alkyl, B_1 alkenyl, B_1 alkinyl, $HOC(O)alkyl$, phenylalkyl and $R_8X_2C(O)-C_1-C_6$ alkyl groups.

Alkyl groups are for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl and the various isomeric pentyl, hexyl, heptyl and octyl radicals. Preferred are methyl, ethyl, n-propyl, isopropyl and n-butyl.

Examples of alkenyls are vinyl, allyl, methallyl, 1-methylvinyl, but-2-en-1-yl, pentenyl, 2-hexenyl, 3-heptenyl and 4-octenyl, preferably alkenyl radicals with a chain length of 3 to 5 carbon atoms.

Examples of alkinyls are ethynyl, propargyl, 1-methylpropargyl, 3-butenyl, but-2-in-1-yl, 2-methylbutin-2-yl, but-3-in-2-yl, 1-pentynyl, pent-4-in-1-yl or 2-hexynyl, preferably alkinyl radicals with a chain length of 2 to 4 carbon atoms.

Alkyl groups substituted once or more, especially once to three times, by halogen are suitable as the halogenalkyl, the halogen being iodine, especially fluorine, chlorine and bromine, for example fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, 2-fluoroethyl, 2,2-difluoroethyl, 2-chloroethyl, 2,2-dichloroethyl, 2,2,2-trifluoroethyl, 2,2,2-trichloroethyl and pentafluoroethyl.

Suitable halogenalkenyls are alkenyl groups substituted once or more by halogen, the halogen being bromine, iodine and especially fluorine and chlorine, for example 2- and 3-

fluoropropenyl, 2- and 3-chloropropenyl, 2- and 3-bromopropenyl, 2,3,3-trifluoropropenyl, 3,3,3-trifluoropropenyl, 2,3,3-trichloropropenyl, 4,4,4-trifluorobut-2-en-1-yl and 4,4,4-trichlorobut-2-en-1-yl. Of the alkenyl radicals substituted once, twice or three times by halogen, those with a chain length of 3 or 4 carbon atoms are preferred. The alkenyl groups may be substituted by halogen on saturated or unsaturated carbon atoms.

Suitable halogenalkinyls are for example alkinyl groups substituted by halogen, the halogen being bromine, iodine and especially fluorine and chlorine, for example 3-fluoropropinyl, 3-chloropropinyl, 3-bromopropinyl, 3,3,3-trifluoropropinyl and 4,4,4-trifluorobut-2-en-1-yl.

Alkylsulfonyl is for example methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, n-butylsulfonyl, isobutylsulfonyl, sec-butylsulfonyl, tert-butylsulfonyl; preferably methylsulfonyl and ethylsulfonyl.

Halogenalkylsulfonyl is for example fluoromethylsulfonyl, difluoromethylsulfonyl, trifluoromethylsulfonyl, chloromethylsulfonyl, trichloromethylsulfonyl, 2-fluoroethylsulfonyl, 2,2,2-trifluoroethylsulfonyl and 2,2,2-trichloroethylsulfonyl.

Halogenalkenylsulfonyl is for example 2- and 3-fluoropropenylsulfonyl, 2- and 3-chloropropenylsulfonyl, 2- and 3-bromopropenylsulfonyl, 2,3,3-trifluoropropenylsulfonyl, 2,3,3-trichloropropenylsulfonyl, 4,4,4-trifluorobut-2-en-1-yl-sulfonyl and 4,4,4-trichlorobut-2-en-1-yl-sulfonyl.

Cyanoalkyl is for example cyanomethyl, cyanoethyl, cyanoeth-1-yl and cyanopropyl.

Hydroxyalkyl is for example hydroxymethyl, 2-hydroxyethyl and 3-hydroxypropyl.

Alkylamino is for example methylamino, ethylamino and the isomeric propyl and butylamino.

Dialkylamino is for example dimethylamino, diethylamino and the isomeric dipropyl and dibutylamino.

Halogenalkylamino is for example chloroethylamino, trifluoroethylamino and 3-chloropropylamino.

Di(halogenalkyl)amino is for example di(2-chloroethyl)-amino.

Alkylcarbonyl is in particular acetyl and propionyl.

Halogenalkylcarbonyl is in particular trifluoroacetyl, trichloroacetyl, 3,3,3-trifluoropropionyl and 3,3,3-trichloropropionyl.

Alkenylcarbonyl is in particular vinylcarbonyl, allylcarbonyl, methallylcarbonyl, but-2-en-1-yl-carbonyl, pentenylcarbonyl and 2-hexenylcarbonyl.

Alkinylcarbonyl is in particular acetylenecarbonyl, propargylcarbonyl, 1-methyl-propargylcarbonyl, 3-butenylcarbonyl, but-2-en-1-yl-carbonyl and pent-4-en-1-yl-carbonyl.

Alkoxy is for example methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy and tert-butoxy; preferably methoxy, ethoxy and isopropoxy.

Alkenyloxy is for example allyloxy, methallyloxy and but-2-en-1-yloxy.

Alkinyloxy is for example propargyloxy and 1-methylpropargyloxy.

Alkoxyalkyl is for example methoxymethyl, methoxyethyl, ethoxymethyl, ethoxyethyl, n-propoxymethyl, n-propoxyethyl, isopropoxymethyl and isopropoxyethyl.

Alkenyloxy is for example allyloxyalkyl, methallyloxyalkyl and but-2-en-1-yloxyalkyl.

Alkoxycarbonyl is for example methoxycarbonyl, ethoxycarbonyl, n-propoxycarbonyl, isopropoxycarbonyl and n-butoxycarbonyl, preferably methoxycarbonyl and ethoxycarbonyl.

Alkenyloxy carbonyl is for example allyloxy carbonyl, methallyloxy carbonyl, but-2-en-1-yl-oxy carbonyl, pentenyloxy carbonyl and 2-hexenyloxy carbonyl.

Alkinyloxy carbonyl is for example propargyloxy carbonyl, 3-butinyloxy carbonyl, but-2-in-1-yl-oxy carbonyl and 2-methylbutin-2-yl-oxy carbonyl.

Alkoxyalkoxy carbonyl is for example methoxymethoxy carbonyl, ethoxymethoxy carbonyl, ethoxyethoxy carbonyl, propoxymethoxy carbonyl, propoxyethoxy carbonyl, propoxypropoxy carbonyl and butoxyethoxy carbonyl.

Halogenalkoxy is for example fluoromethoxy, difluoromethoxy, trifluoromethoxy, 2,2,2-trifluoroethoxy, 1,1,2,2-tetrafluoroethoxy, 2-fluoroethoxy, 2-chloroethoxy and 2,2,2-trichloroethoxy.

The cycloalkyl radicals suitable as substituents are for example cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The cycloalkoxy carbonyl radicals suitable as substituents are for example cyclopropoxy carbonyl, cyclobutoxy carbonyl, cyclopentoxy carbonyl and cyclohexyloxy carbonyl.

Alkylthio is for example methylthio, ethylthio, propylthio and butylthio, as well as the branched isomers thereof.

Alkylthioalkyl is for example methylthioethyl, ethylthioethyl, methylthiopropyl and ethylthiopropyl.

Halogenalkylthiocarbonyl is for example fluoromethylthiocarbonyl, difluoromethylthiocarbonyl, trifluoromethylthiocarbonyl, 2,2,2-trifluoroethylthiocarbonyl, 1,1,2,2-tetrafluoroethylthiocarbonyl, 2-fluoroethylthiocarbonyl, 2-chloroethylthiocarbonyl and 2,2,2-trichloroethylthiocarbonyl.

Corresponding meanings may also be ascribed to the substituents in the listed definitions, such as, for example, halogenalkenyl carbonyl, halogenalkinyl carbonyl, $R_{40}O-$, $R_4C(O)-$, $R_{11}X_3C(O)-$, $R_{13}X_4C(O)-$, $R_{14}X_5C(O)-$, $R_5X_1C(O)-$, $R_8X_2C(O)-$ alkyl, $R_8X_2C(O)-$ cycloalkyl,

$R_{41}S(O)_{n2}-$, R_6-N- , R_7-ON- , $R_{42}(R_{43})N-$, $R_{45}(R_{46})N-C(R_{44})=N-$, B_1 alkyl, B_1 alkenyl,

B_1 alkinyl, B_1 halogenalkyl, B_1 halogenalkenyl, B_1 alkoxyalkyl, B_1 alkylthioalkyl, B_1 cycloalkyl and $B_2-C(R_{12})=CH-$.

In the definition of R_5 , the groups $C_1-C_6\text{-Alkyl-C(O)-[C}_1\text{-C}_4\text{-alkylen]-}$
 $\begin{array}{c} | \\ (C_6H_5) \end{array}$ and

$R_5X_2C(O)-[C_1-C_6\text{-alkylen]-}$
 $\begin{array}{c} | \\ (C_6H_5) \end{array}$ mean that the $C_1-C_6\text{alkyl-C(O)-}$ or $C_1-C_6\text{alkylene}$ chain is in

addition substituted by phenyl (C_6H_5) on one of the 4 or 6 carbon atoms, wherein the phenyl ring is substituted once to three times by halogen, $C_1-C_4\text{alkyl}$ or $C_1-C_4\text{halogenalkyl}$, and the alkylene chain may be straight-chained or branched and may, for example, be methylene, ethylene, methylethylene, propylene, 1-methylpropylene and butylene.


In the definitions cyanoalkyl, alkylcarbonyl, alkenylcarbonyl, halogenalkenylcarbonyl, alkenylcarbonyl, alkoxy carbonyl, alkoxy carbonylalkyl and halogenalkylcarbonyl, the cyano- and carbonyl carbon atoms are not included in the upper and lower limits of the carbon number.

L in the reagents of formulae XII, XXI, XXIVa, XXIVb and XXXV is a leaving group, such as halogen, for example, preferably chlorine, bromine or iodine, $C_1-C_3\text{alkyl-}$ or arylsulfonyloxy,

preferably CH_3SO_2O- or $CH_3-\text{C}_6\text{H}_4-SO_2O-$, or $C_1-C_6\text{alkylcarbonyloxy}$, preferably


acetyloxy.

L_1 in the reagent of formula XIII is a leaving group such as, for example, $HOS(O)_2O-$,



L_2 in the reagents of formulae XXVa and XXVc is a leaving group such as, for example, hydroxy, $C_1-C_4\text{alkoxy}$ or halogen, preferably chlorine, bromine or iodine.

L_3 in the reagent of formula XXXI is a leaving group such as chlorine or bromine,

trichloromethoxy or .

L_4 in the compounds of formulae II and III (reaction schemes 1 and 2) is a leaving group such as, for example, halogen, typically fluorine, chlorine or bromine or $C_1-C_4\text{alkyl-}$ or phenylsulfonyl or $C_1-C_4\text{alkyl-}$, $C_1-C_4\text{halogenalkyl-}$ or phenylsulfonyloxy.

R₃₃ together with R₃₂ (group W₇) forms a C₃-C₅alkylene bridge which may be broken for example by oxygen and substituted by =O, and is illustrated by way of example in Tables 127 (compound of formula I₁₂₇), 130 (compound of formula I₁₃₀), 136 (compound of formula I₁₃₆) and 137 (compound of formula I₁₃₇).

The invention relates also to the salts which the compounds of formula I with acidic hydrogen, especially the derivatives with carboxylic acid groups (for example, carboxyl-substituted alkyl, alkylene, alkenyl, alkynyl, alkoxyalkyl, alkylthioalkyl and cycloalkyl groups) may form with bases. These salts are, for example, alkali metal salts, such as sodium and potassium salts; earth alkali metal salts, such as calcium and magnesium salts; ammonium salts, i.e. unsubstituted ammonium salts and monosubstituted or polysubstituted ammonium salts, such as triethylammonium and methylammonium salts; or salts with other organic bases.

Salt-forming alkali metal and alkaline earth metal bases include the hydroxides of lithium, sodium, potassium, magnesium or calcium, those of sodium and potassium being especially preferred. Suitable salt-forming substances are described for example in WO 97/41112.

Examples of amines suitable for forming ammonium salts are ammonia, as well as primary, secondary, and tertiary C₁-C₁₈alkylamines, C₁-C₄hydroxyalkylamines and C₂-C₄alkoxyalkylamines, typically methylamine, ethylamine, n-propylamine, isopropylamine, the four isomeric butylamines, n-amylamine, isoamylamine, hexylamine, heptylamine, octylamine, nonylamine, decylamine, pentadecylamine, hexadecylamine, heptadecylamine, octadecylamine, methyl ethylamine, methyl isopropylamine, methyl hexylamine, methyl nonylamine, methyl pentadecylamine, methyl octadecylamine, ethyl butylamine, ethyl heptylamine, ethyl octylamine, hexyl heptylamine, hexyl octylamine, dimethylamine, diethylamine, di-n-propylamine, diisopropylamine, di-n-butylamine, di-n-amylamine, diisoamylamine, dihexylamine, diheptylamine, dioctylamine, ethanolamine, n-propanolamine, isopropanolamine, N,N-diethanolamine, N-ethylpropanolamine, N-butylethanolamine, allylamine, n-butenyl-2-amine, n-pentenyl-2-amine, 2,3-dimethylbutenyl-2-amine, dibutenyl-2-amine, n-hexenyl-2-amine, propylenediamine, trimethylamine, triethylamine, tri-n-propylamine, triisopropylamine, tri-n-butylamine, triisobutylamine, tri-sec-butylamine, tri-n-amylamine, methoxyethylamine and ethoxyethylamine; heterocyclic amines such as pyridine, quinoline, isoquinoline, morpholine, thiomorpholine, piperidine, pyrrolidine, indoline, quinuclidine and azepine; primary arylamines such as anilines, methoxyanilines, ethoxyanilines, o-, m- and p-toluidines, phenylenediamines, benzidines, naphthylamines and o-, m- and p-chloroanilines; but especially triethylamine, isopropylamine and diisopropylamine.


The salts of compounds of formula I with basic groups, especially with basic pyridyl and pyrazolyl rings (W3 and W4), or of derivatives with amino groups, e.g. amino, alkylamino and dialkylamino groups in the definition of R_2 , W_1 or W_3 (R_{15} , R_{21} , R_{22}) are, for example, salts with inorganic and organic acids, for example hydrogen halides, such as hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydriodic acid, as well as sulfuric acid, phosphoric acid, nitric acid and organic acids, such as acetic acid, trifluoroacetic acid, trichloroacetic acid, propionic acid, hydroxyethanoic acid, thiocyanic acid, citric acid, benzoic acid, oxalic acid, formic acid, benzenesulfonic acid, p-toluenesulfonic acid and methanesulfonic acid

The presence of at least one asymmetric carbon atom in the compounds of formula I, for example in substituent $R_3 = R_5X_1C(O)-$, wherein R_5 is a branched alkyl, alkenyl, halogenalkyl or alkoxyalkyl group, or $R_3 = B_1-C_3-C_6$ cycloalkyl, wherein for example B_1 is C_1-C_8 alkoxy or $R_{11}X_3C(O)-$, means that the compounds may occur both in single optically active isomers and also in the form of racemic mixtures. In the present invention, the active substances of formula I are understood to include both the pure enantiomers and the racemates or diastereomers.

If an aliphatic $C=C$ double bond is present (e.g. in substituent $R_3 = B_2-C(R_{12})=CH-$), then geometric isomerism may occur. The present invention also relates to these isomers.

Compounds of formula I are preferred wherein R_2 is methyl, halogen, hydroxy, nitro, amino or cyano.

Also preferred are compounds of formula I wherein W is the group




and R_{15} , R_{16} , R_{17} , X_6 and X_7 are as defined under formula I.


Especially preferred are those compounds wherein R_{15} is methyl; R_{16} is trifluoromethyl; R_{17} is hydrogen; and X_6 and X_7 are oxygen.

Likewise preferred are compounds of formula I wherein R_1 is fluorine or chlorine; R_2 is chlorine, bromine or cyano; and R_3 is $R_5X_1C(O)-$, wherein R_5 has the meaning defined under formula I; and X_1 is oxygen or sulfur. Of these compounds, those wherein R_2 is chlorine are especially important.

The method described in the invention for the preparation of compounds of formula I,



wherein R_1 , R_2 , R_3 , A and W are as defined under formula I, is carried out by analogy with known methods, such as those described for example in WO 97/00246, WO 96/01254 and International Patent Application Number PCT/EP 97/06243, and comprises treating a compound of formula II




wherein R_1 , R_2 and W have the meanings indicated, and L_4 is a leaving group such as halogen, either

a) in a suitable solvent, where appropriate in the presence of a base such as a trialkylamine, a palladium or nickel catalyst and a compound of formula V



wherein R_5 is hydrogen or C_1 - C_4 alkyl, in an autoclave under positive pressure with carbon monoxide, or

b) in a suitable solvent in the presence of a tertiary amine, a palladium catalyst, and an olefin by means of the Heck reaction, or under said conditions by means of reaction with a Grignard reagent of formula Va




wherein R_3 is B_1 - C_1 - C_8 alkyl, B_1 - C_2 - C_8 alkenyl, B_1 - C_2 - C_8 alkinyl, B_1 - C_1 - C_8 halogenalkyl, B_1 - C_2 - C_8 halogenalkenyl, B_1 - C_1 - C_4 alkoxy- C_1 - C_4 alkyl, B_1 - C_1 - C_4 alkylthio- C_1 - C_4 alkyl or B_1 - C_3 - C_6 cycloalkyl and B_1 is as defined under formula I, or in an inert solvent and in the presence of a catalyst, such as palladium-bis-triphenylphosphine dichloride ($Pd(C_6H_5)_2Cl_2$), in a manner analogous to that described in Synlett 1998, 1185, with a tin compound of formula Vb



wherein R_3 has the meaning indicated, or


c) where applicable in an inert solvent at reaction temperatures of 20–300°C subjecting it to a cyanidation reaction, e.g. with an alkali metal cyanide or a cyanide whose metal ion

belongs to the first or second subgroup of the periodic system, such as copper cyanide, in a manner analogous to that described in J. Het. Chem. 11, 397 (1974), or
 d) first oxidizing it in a suitable solvent to form a compound of formula IV




and treating this in an inert solvent with dimethylcarbamoyl chloride and a cyanidation reagent, and then where applicable further functionalizing it according to the definitions of A and R₃.


The method described in the invention for the preparation of compounds of formula I,




wherein R₁, R₂, R₃ and A are as defined under formula I, W is a W₁ group



corresponding to a compound of formula Ia in reaction scheme 2, is carried out by analogy with the known methods such as those described for example in EP-A-0 438 209 or DE-OS-19 604 229, and comprises reacting a compound of formula III




wherein R₁, R₂ and R₃ have the meanings indicated, and L₄ is a leaving group, such as halogen, for example fluorine, chlorine or bromine, in the presence of an inert solvent and ammonia if necessary in an autoclave at temperatures of -10 to 180°C to form a compound of formula VI




reacting this in the presence of a base and a solvent


a) with a chloroformate of formula VII




wherein X₆ is as defined under formula I, to form a compound of formula VIII




b) with oxalyl chloride, phosgene or thiophosgene to form a compound of formula IX



followed by cyclization of a compound of formula VIII or IX in the presence of 0.1–1.5 equivalents of a base in an inert solvent with an enamine derivative of formula X



wherein R₁₆ and R₁₇ are as defined under formula I, and X₇ is oxygen, and a resulting compound of formula XI



wherein R_1 , R_2 , R_3 , R_{16} , R_{17} , X_6 and X_7 have the meanings indicated, and further reacting this compound in the presence of an inert solvent and a base with

c) a compound of formula XII




wherein R_{15} is C_1 - C_3 alkyl or C_1 - C_3 halogenalkyl, and L is a leaving group, or


d) with a hydroxylamine derivative of formula XIII




wherein L_1 is a leaving group, and subsequently performing if necessary oxidation (A



The method described in the invention for the preparation of compounds of formula I,




wherein R_1 , R_2 , R_3 , and A are as defined under formula I, W is a W_2 group




corresponding to a compound of formula Ib in reaction scheme 3, is carried out by analogy with known methods, such as those described for example in DE-A-4 423 934 and JP-A-58 213 776, and comprises either


a) reacting a compound of formula III,



wherein R_1 , R_2 and R_3 have the meanings indicated, and L_4 is a leaving group such as halogen, for example fluorine, chlorine or bromine, with hydrazine, preferably in an amphiprotic solvent, to form a compound of formula XIV




further reacting this with a compound of formula XV or XVa



wherein R_{18} and R_{19} have the meanings defined under formula I, and Hal in a compound of formula XVa is chlorine or bromine, or


b) first diazotizing a compound of formula VI,




wherein R_1 , R_2 and R_3 have the meanings indicated, then further reacting it with a compound of formula XVI



wherein R_{18} and R_{19} have the meanings indicated, and obtaining a compound of formula XVII




which if necessary is cyclized in the presence of a base, such as 4-dimethylaminopyridine and a compound of formula XVIII




wherein R_{20} has the meaning indicated, and X_8 is oxygen, and subsequently performing if

necessary oxidation ($A = \overset{+}{N}=\overset{-}{O}$).

The method described in the invention for the preparation of compounds of formula I,




wherein R_1 , R_2 , R_3 and A are as defined under formula I, W is a W_7 group




corresponding to a compound of formula Ig in reaction scheme 4, is carried out by analogy with known methods, such as those described for example in EP-A-0 272 594, EP-A-0 493 323, DE-A-3 643 748, WO 95/23509, US-A-5 665 681 and US-A-5 661 109, and comprises for example either

a) reacting a compound of formula VIIIa




in the presence of a solvent and a base, or


b) a compound of formula IXa



if necessary in a suitable solvent, wherein the radicals R_1 , R_2 , R_3 and X_{14} in compounds of formula VIIIa and IXa have the meanings indicated, with a compound of formula XIX



wherein R_{31} , R_{32} , R_{33} and X_{13} have the meanings indicated, and obtaining a compound of formula XX



cyclizing this in the presence of a suitable solvent and a base and then where applicable


c) if R_{33} is hydrogen, reacting it with a compound of formula XXI




wherein R_{33} is $\text{C}_1\text{-C}_3$ alkyl, and L is a leaving group, and subsequently performing if

necessary oxidation ($\text{A} = \text{N}^+ = \text{O}^-$) and thionization.

The method described in the invention for the preparation of compounds of formula I,




wherein R_1 , R_2 , R_3 and A are as defined under formula I, W is a W_8 group




corresponding to a compound of formula Ih in reaction scheme 5, is carried out by analogy with known methods, such as those described for example in EP-A-0 210 137, DE-A-2 526 358, EP-A-0 075 267 and EP-A-0 370 955, and comprises

a) reacting a compound of formula VIIIb




in the presence of a solvent and a base, or


b) a compound of formula IXb



wherein the radicals R_1 , R_2 , R_3 and X_{15} in compounds of formula VIIIb and IXb have the meanings indicated, if necessary in a suitable solvent, with a compound of formula XXII




wherein R_{34} , R_{35} , and X_{16} have the meanings indicated, and obtaining a compound of formula XXIII



cyclizing this in the presence of a suitable solvent and a base and then where applicable


c) if R_{34} and/or R_{35} are/is hydrogen, further reacting it with a compound of formula XXIVa or XXIVb




wherein R_{34} and R_{35} are independently $\text{C}_1\text{-C}_3$ alkyl, and L is a leaving group, or with a

Michael acceptor, and then if necessary oxidizing ($\text{A} = \text{N}^+ = \text{O}^-$) and thionizing it.


The method described in the invention for the preparation of compounds of formula I,



wherein R_1 , R_2 , R_3 and A are as defined under formula I, W is a W_3 group




corresponding to a compound of formula Ic in reaction scheme 6, is carried out by analogy with known methods, such as those described for example in WO 97/07114, US-A-5 306 694, DE-A-3 832 348, EP-A-0 257 479 and EP-A-0 500 209, and comprises condensing a compound of formula XIV




wherein R_1 , R_2 and R_3 have the meanings indicated, for example

a) with a compound of formula XXV




wherein R_{21} is hydrogen, C_1 - C_3 alkyl or C_1 - C_3 halogenalkyl; R_{22} is hydrogen, C_1 - C_4 alkyl, C_1 - C_4 halogenalkyl, C_2 - C_4 alkenyl, C_3 - C_5 halogenalkenyl or C_3 - or C_4 alkinyl; and R_{23} is hydrogen, C_1 - C_4 alkyl or C_1 - C_4 halogenalkyl, if necessary in the presence of an acidic, basic or bifunctional catalyst such as p-toluenesulfonic acid, for example, or


b) with a compound of formula XXVa



wherein R_{22} and R_{23} have the meanings indicated, and L_2 is a suitable leaving group, to form a compound of formula XXVI




and further functionalizing the pyrazolone group in accordance with the definition of R_{21} in a manner analogous to known methods, for example using a halogenation agent such as phosphorus oxychloride, to form the corresponding halogen derivative of formula Ic




wherein R_1 , R_2 , R_3 , R_{22} and R_{23} have the meanings indicated, and R_{21} is halogen, and

subsequently performing if necessary oxidation ($A = \overset{+}{N} - \overset{-}{O}$).


The method described in the invention for the preparation of compounds of formula I,



wherein R_1 , R_2 , R_3 and A are as defined under formula I, W is a W_4 group




corresponding to formula Id in reaction scheme 7, is carried out by analogy with known methods such as those described for example in EP-A-0 370 332, EP-A-0 370 955 or DE-A-3 917 469, and comprises condensing a compound of formula XIV




wherein R_1 , R_2 and R_3 have the meanings indicated,

a) with a compound of formula XXVb




wherein R_{25} and R_{26} have the meanings indicated, and R_{24} is hydrogen, C_1 - C_4 alkyl or C_1 - C_4 halogenalkyl, if necessary in the presence of a catalyst, or


b) with a compound of formula XXVc



wherein R_{25} and R_{26} have the meanings indicated, and L_2 is a suitable leaving group, to form a compound of formula XXVIa



and treating this compound with a halogenation agent, such as phosphoroxy halogenide or thionyl halogenide, and obtaining a compound of formula Id




wherein R_1 , R_2 , R_3 , R_{25} and R_{26} have the meanings indicated and R_{24} is halogen, and reacting this compound if necessary with a cyanide of formula XXVII





wherein M is an ammonium cation, alkali metal ion or metal ion of the first or second subgroup of the periodic system, and s is the number 1 or 2, where applicable in the presence of an alkali metal iodide ($R_{24} = \text{cyano}$; reaction scheme 7), and subsequently

performing if necessary oxidation ($A = \text{N}^+ \text{O}^-$).

The method described in the invention for the preparation of compounds of formula I,



wherein R_1 , R_2 , R_3 and A are as defined under formula I, W is a W_5




defined under formula I, corresponding to compounds of formula Ie and If in reaction scheme 8, is carried out by analogy with known methods, such as those described for example in DE-A-3 917 469, WO 92/00976, US-A-5 069 711 and EP-A-0 260 228, and comprises for example

a) reacting a compound of formula XXVIII




b) a compound of formula XXVIIIa




(XXVIIIa),

wherein radicals R_{27} to R_{30} in compounds of formulae XXVIII and XXVIIIa have the meanings indicated, with a compound of formulae VI




(VI),

wherein R_1 , R_2 and R_3 have the meanings indicated, in an inert solvent in the presence of a C_1 - C_4 alkylcarboxylic acid at temperatures of 20° to 200°C and reacting the resulting compounds of formulae Ie and If



(Ie) and




(If),

wherein R_1 to R_3 and R_{27} to R_{30} have the meanings indicated, and X_9 to X_{12} are oxygen, if necessary with the aid of a suitable sulfur reagent to form the corresponding thiono compound of formulae Ie and If, wherein X_9 and/or X_{10} , X_{11} , X_{12} , are sulfur, and oxidizing the


said compound (A $\begin{array}{c} + \\ =N-O^- \\ | \end{array}$, reaction scheme 8).

The method described in the invention for the preparation of compounds of formula I




(I),

wherein R_1 , R_2 , R_3 , and A are as defined under formula I, W is a W_9 group




(W_9), and R_{36} , R_{37} , X_{17} , and X_{18} are as defined under formula I, corresponding to a compound of formula II in reaction scheme 9, is carried out by analogy with known methods, such as those described for example in WO 95/00521, EP-A-0 611 708 and WO 94/25467, and comprises for example reacting

a) a compound of formula VIIIc




b) a compound of formula IXc



wherein the radicals R_1 , R_2 , R_3 and X_{18} in compounds of formulae VIIIc and IXc have the meanings indicated, if necessary in the presence of a suitable solvent and a base, with a compound of formula XXIX



wherein R_{36} and R_{37} are as defined under formula I, and obtaining a compound of formula XXX




and subsequently reacting this, if necessary in a solvent and in the presence of a base, with a (thio-)carbonylation reagent of formula XXXI




wherein X_{17} has the meaning indicated, and L_3 is a leaving group (reaction scheme 9), and

subsequently performing if necessary oxidation ($\text{A} = \text{N}^+ \text{O}^-$).


The method described in the invention for the preparation of compounds of formula I



wherein R_1 , R_2 , R_3 and A are as defined under formula I, W is a W_{10} group




corresponding to a compound of formula Ik in reaction scheme 10, is carried out by analogy with known methods, such as those described for example in US-A-5 980 480, DE-A-3 917 469, US-A-4 818 275, US-A-5 041 155 und EP-A-0 610 733, and comprises, for example, a) reacting a compound of formula XIV



if necessary in the presence of a catalyst, with a compound of formula XXXII



to form a compound of formula XXXIII




wherein the radicals R_1 , R_2 , R_3 and R_{39} in the compounds of formulae XIV, XXXII and XXXIII have the meanings indicated, and further cyclizing this compound with an azide of formula XXXIV




($X_{19} = O$, $R_{38} = H$), or

b) cyclizing a compound of formula XIV




with a compound of formula XXXVI



wherein the radicals R_1 , R_2 , R_3 and R_{39} in the compounds of formulae XIV and XXXVI have the meanings indicated, ($X_{19} = O$, $R_{38} = H$), or


c) cyclizing a compound of formula XIV




first with a compound of formula XXXVII




to form a compound of XXXIIa



then with an alkali metal cyanate to form a compound of XXXVIII



and finally cyclizing this compound in the presence of an oxidation agent and obtaining a compound of formula Ik




wherein R_1 , R_2 , R_3 and R_{39} have the meanings indicated, X_{19} is oxygen, and R_{38} is hydrogen, and treating this compound if necessary with a sulfur reagent ($X_{19} = S$) and in the presence of a base with an alkylation reagent of formula XXXV













wherein R_{38} is C_1 - C_4 alkyl, C_1 - C_4 halogenalkyl, C_3 - or C_4 alkenyl, C_3 - or C_4 halogenalkenyl or C_3 - or C_4 alkinyl, and L is a leaving group, and subsequently performing if necessary

oxidization (A $\begin{array}{c} + \\ \parallel \\ N-O^- \\ | \end{array}$) and thionization.

The method described in the invention for the preparation of compounds of formula I is carried out in a manner analogous to known methods and comprises, for example, reacting a compound of formula III



wherein R_1 , R_2 and R_3 are as defined under formula I, and L_4 is a leaving group, such as a halogen, for example fluorine, chlorine or bromine, with a compound of W_{01} , W_{02} , W_{03} , W_{04} , W_{05} , W_{06} , W_{07} , W_{08} , W_{09} or W_{010}


(W₀₁),(W₀₂),(W₀₃),(W₀₄),(W₀₅),(W₀₆),(W₀₇),(W₀₈),(W₀₉) or

(W₀₁₀), wherein R_{15} to R_{39} and X_6 to X_{19} are as defined under formula I,

if necessary in the presence of a suitable solvent and base, and if necessary subjecting the







obtainable compounds of formula I ($A = N-$) to oxidation ($A = \overset{+}{N}-O^-$) and thionization.

The method described in the invention for the preparation of compounds of formula II




(II),


wherein R_1 and R_2 are as defined under formula I, W is a



defined under formula I, and L_4 is a leaving group, such as halogen for example, especially chlorine or bromine, is carried out in a manner analogous to known methods and comprises, for example, first oxidizing a compound of formula XXXIX




in a suitable solvent to form a compound of formula XXXX



wherein radicals R_1 , R_2 and W in the compounds of formulae XXXIX and XXXX have the meanings indicated, and then subjecting the compound either to


- halogenation, for example with phosphorus oxychloride, if necessary in the presence of a base and a suitable solvent, or
- transformation in an inert solvent in the presence of an anhydride or antimony pentachloride, and following aqueous treatment, to form a compound of XXXXI



(so-called Katada reaction), and the halogenation of this compound if necessary in the presence of a base and a suitable solvent as described under variant a).



The above methods of preparation are explained in more detail in the following reaction schemes 1 to 12.


The preparation of a compound of formula I



wherein R_1 to R_3 , A and W are as defined under formula I, is explained in the following reaction scheme 1:

Reaction scheme 1:





The pyridine derivatives of formula I, wherein R_3 is a $HOOC-$ or R_5OOC group, may be prepared according to variant a) in reaction scheme 1 in a manner analogous to known methods, a useful method being to react for example the 6-halogen pyridine ($L_4 = \text{halogen}$) of formula II in the presence of a palladium or nickel catalyst, such as a palladium triphenylphosphine complex ($PdCl_2(PPh_3)_2$), with carbon monoxide under pressure in an autoclave, if necessary in the presence of an alcohol of formula V



and a base, such as a trialkylamine, for example triethylamine.


According to variant b) in reaction scheme 1, pyridine derivatives of formula I, wherein R_3 is a $B_1-C_2-C_8\text{alkenyl}$, $B_1-C_2-C_8\text{alkinyl}$ or $B_2-C(R_{12})=CH$ group, are obtainable in a manner analogous to known methods, such as those described in "Transition Metals in Organic Synthesis", Editor S. Gibson, Oxford Press, 1997, for example starting from a 6-halogen pyridine of formula II ($L_4 = \text{halogen}$) under the conditions of the Heck reaction with an olefin in the presence of a palladium catalyst, such as palladium(II) acetate ($Pd(CH_3COO)_2$), a tertiary amine, such as triethylamine, and a solvent.

According to variant c) in reaction scheme 1, pyridine derivatives of formula I, wherein R_3 is a cyano group, are obtainable for example directly by reacting for example the 6-halogen pyridine of formula II (L_4 = halogen) with a cyanidation reagent such as an alkali metal cyanide, for example potassium or sodium cyanide, a transition metal cyanide, for example copper cyanide, a tetraalkylammonium cyanide or trialkylsilyl cyanide, for example trimethylsilyl cyanide, in an inert solvent.

According to variant d) in reaction scheme 1, a reactivation for example of the 6-halogen pyridine of formula II (L_4 = halogen) first takes place via oxidation to form the corresponding pyridine-N-oxide of formula IV and the reaction thereof with dimethylcarbamoyl chloride to form the reactive 1-carbamoyloxypyridinium salt. The following reaction of this pyridinium salt with a cyanidation reagent is carried out in a manner analogous to that described under c). Such cyanidation reactions are described for example in Heterocycles 22, 1121 (1984), J.Org.Chem. 48, 1375 (1983) and US-A-4 776 219.


Further derivatization of the pyridine derivatives of formula I, primarily obtainable according to variants a) to d) in reaction scheme 1, wherein R_3 is a carboxyl, alkoxy-carbonyl, alkenyl or alkynyl, or cyano group, and A is nitrogen, can be readily accomplished, taking into account the chemical reactivities of the pyridyl and W parts (groups W_1 to W_{10}), in a manner analogous to known standard methods, such as esterification, transesterification, hydrolysis, oxidative or reductive processes, or condensation reactions, for example the Wittig-Horner reaction. Such standard methods are described for example in WO 93/06090, EP-A-0 240 659 and in Houben-Weyl, "Methoden der Organischen Chemie", Vol. E1, Thieme Verlag Stuttgart, 1982.

The preparation of a compound of formula Ia



wherein R_1 , R_2 , R_3 , R_{15} , R_{16} , R_{17} , X_6 and X_7 are as defined under formula I, is explained in the following reaction scheme 2.

Reaction scheme 2:



For the preparation of the compounds of formula Ia according to the invention, many known standard methods are available, such as those described for example in EP-A-0 438 209 and DE-OS-19 604 229 ($\text{R}_{16} = \text{Cyano}$). In reaction scheme 2, a selection of suitable preparative processes is shown, wherein the choice of reaction pathways and reagents depends on the reactivities of the substituents in the intermediate stages.

Starting for example from a compound of formula III, the aminopyridine of formula VI can be obtained by reacting with ammonia in an inert solvent, if necessary in an autoclave at temperatures from -10 to 180°C . This aminopyridine can be reacted in the presence of a base and a solvent either

a) with a chloroformate of formula VII ($X_6 = O$ or S) to form a pyridyl carbamate of formula VIII, or


b) with oxalyl chloride, phosgene ($X_6 = O$) or thiophosgene ($X_6 = S$) to form an iso(thio)cyanate of formula IX. Such reactions are described for example in Angew. 1971, 407.

The carbamate and iso(thio)cyanate of formulae VIII and IX can be cyclized in the presence of the enamine derivative of formula X in an inert solvent to form the uracil derivative of formula XI, the reaction of the iso(thio)cyanate of formula IX being advantageously carried out in the presence of 0.1-1.5 equivalents of a base, for example sodium hydride, potassium tert-butyrate or alkaline earth metal oxide or hydroxide, for example barium hydroxide.

The desired compounds of formula Ia can be prepared from the uracils of formula XI, according to standard methods, in the presence of an inert solvent and at least 1 equivalent of a base, for example an alkali metal carbonate such as potassium carbonate,


c) with an alkylation agent of formula XII to form an N-alkyl derivative of formula Ia ($R_{15} = \text{alkyl}$), or

d) in analogy to WO 97/05116 with a hydroxylamine derivative of formula XIII, wherein L_1 is




example 2,4-dinitrophenylhydroxylamine or hydroxylamine-O-sulfonic acid, to form the N-amino derivative of formula Ia ($R_{15} = \text{amino}$). The desired thiono derivatives of formula Ia ($X_6, X_7 = S$) can be obtained by thionization, for example with phosphorus pentasulfide or Lawesson's reagent.

The preparation of a compound of formula Ib



wherein $R_1, R_2, R_3, R_{18}, R_{19}, R_{20}$, and X_8 are as defined under formula I, is explained in the following reaction scheme 3.

Reaction scheme 3:




The compounds of formula Ib can be prepared according to known methods, for example according to reaction scheme 3 (variant a)) by reacting a 2-halogen pyridine derivative of formula III (L4=halogen) with hydrazine, preferably in an amphiprotic solvent, such as alcohols, by analogy with GB-A-2 230 261, to form the 2-hydrazino derivative of formula XIV.

This is reacted with a diketone of formula XV, by analogy with DE OS-19754348, or with a dihalogen ketone of formula XVa, by analogy with WO 97/07104, to form the hydrazone derivative of formula XVII.

Subsequent cyclization to the desired compound of formula Ib takes place in the presence of the phosphoran derivative of formula XVIII, if necessary in the presence of a base, for example 4-dimethylaminopyridine. If $X_8 = O$ in a compound of formula Ib, then thionization can subsequently be carried out in a manner similar to that described under reaction scheme 2 ($X_8 = S$).


According to reaction scheme 3, the hydrazone derivative of formula XVII can also be obtained from the 2-aminopyridine derivative of formula VI by means of diazotization, preferably under exclusion of water, and subsequent coupling with the keto acid of formula XVI (Japp-Klingemann reaction similar to that described under DE-OS-19754348) – (variant b) in reaction scheme 3).

The preparation of a compound of formula Ig



wherein R_1 , R_2 , R_3 , R_{31} , R_{32} , R_{33} , and X_{14} are as defined under formula I, is explained in the following reaction scheme 4.

Reaction scheme 4:




Compounds of formula Ig can be prepared in a manner analogous to known methods, as described, for example, in EP-A-0 272 594, EP-A-0 493 323, DE-A-3 643 748, WO 95/23509, US-A-5 665 681 or US-A-5 661 109.

For example, according to reaction scheme 4, either

- a) a carbamate derivative of formula VIIIa in the presence of a solvent and a base, or
- b) an iso(thio)-cyanate of formula IXa, if necessary in a suitable solvent, can be cyclized with an amino acid derivative of formula XIX via a compound of formula XX in the presence of a base and a suitable solvent to form a compound of formula Ig.


For those cases (variant c)) where, in a compound of formula Ig, R₃₃ is hydrogen and X₁₃ and/or X₁₄ are/is oxygen, alkylation can subsequently be carried out, if necessary with an alkylation reagent of formula XXI, on the free N-atom of the hydantoin ring and the ring carbonyl group then thionized (X₁₃ and/or X₁₄ = S).

The preparation of a compound of formula Ih



(Ih),

wherein R₁, R₂, R₃, R₃₄, R₃₅, X₁₅, and X₁₆ are as defined under formula I, is explained in the following reaction scheme 5.




a) a carbamate derivative of formula VIIIb in the presence of a solvent and a base, or

b) an iso(thio-)cyanate of formula IXb, if necessary in a suitable solvent, can be cyclized with a carbazate of formula XXII via a compound of formula XXIII in the presence of a base and a suitable solvent to form a compound of formula Ih.


For those cases (variant c)) where, in a compound of formula Ih, R_{34} and/or R_{35} are/is hydrogen and X_{15} and/or X_{16} are/is oxygen, alkylation can subsequently be carried out with an alkylation reagent of formula XXIVa or XXIVb on the free N-atoms and the ring carbonyl groups then thionized with a thionization reagent (X_{15} and/or $X_{16} = S$)

For the preparation of compounds of formula Ih in reaction scheme 5, wherein R_{34} and R_{35} together form an alkylene bridge which is broken for example by $-S(O)_2-$, a compound of formula Ih, wherein R_{34} and R_{35} are hydrogen, can be reacted for example with an appropriate Michael acceptor, e.g. $CH_2=CH-S(O)_2CH_3$ or $CH_2=CH-S(O)_2-CH=CH_2$, and the resulting Michael addition products then functionalized.

The preparation of a compound of formula Ic



wherein R_1 , R_2 , R_3 , and R_{21} to R_{23} are as defined under formula I, is explained in the following reaction scheme 6.


Reaction scheme 6:

According to reaction scheme 6, the pyrazol compounds of formula Ic can be prepared e.g. either from the hydrazinopyridine derivatives of formula XIV by means of condensation with a 1,3-dicarbonyl derivative of formula XXV (variant a)), or by means of condensation with a β-carbonylcarboxylic acid derivative of formula XXVa, where L₂ is a leaving group, such as C₁-C₄alkoxy, hydroxy or halogen, for example chlorine or bromine (variant b)), and subsequent treatment of the resulting pyridylpyrazolone derivative of formula XXVI with a halogenation agent, for example phosphorus oxychloride (R₂₁ = halogen). The two reaction steps a) and b) in reaction scheme 6 are carried out if necessary in the presence of an acidic, basic or bifunctional catalyst, such as p-toluenesulfonic acid.

The compounds of formula Ic obtained in this way can be further functionalized using standard methods according to the definition of substituents R₂₁ to R₂₃.


Compounds of formula Ic in reaction scheme 6, wherein R₂₂ is hydrogen, can be further functionalized according to the definition of R₂₂, e.g. using an electrophilic reagent, for example a halogenation agent, such as an elementary halogen or sulfurylhalogenide, to form the corresponding compounds of formula Ic, wherein R₂₂ is halogen, or using a nitrating agent such as nitric acid in a mixture with a further strong acid, such as sulfuric acid, to form the corresponding compounds of formula Ic, wherein R₂₂ is nitro.

The preparation of a compound of formula Id



wherein R_1 , R_2 , R_3 , and R_{24} to R_{26} are as defined under formula I, is explained in the following reaction scheme 7.

Reaction scheme 7:




According to reaction scheme 7, the tetrahydroindazol compounds of formula Id can be obtained by known methods from the hydrazinopyridine derivatives of formula XIV, for example either by means of condensation with a cyclohexanone derivative of formula XXVb acylated in the 2-position, wherein R_{24} is as defined under formula I, except where R_{24} is halogen or cyano (variant a)), or by means of condensation with a cyclohexanone derivative of formula XXVc, wherein L_2 is a leaving group, such as C_1 - C_4 alkoxy, hydroxy or halogen,


for example chlorine or bromine, and subsequent halogenation (variant b)) in a manner analogous to that described under reaction scheme 6.

The halogen derivatives of formula Id, wherein R_{24} is halogen, can be reacted according to known methods with an alkali metal, ammonium or metal cyanide, wherein the metal ion is selected from the first or second subgroup of the periodic system, if necessary with the addition of an alkali metal iodide, to form the corresponding cyano-substituted derivatives of formula Id ($R_{24} = \text{CN}$).

The preparation of compounds of formulae Ie and If




wherein R_1 , R_2 , R_3 , R_{27} to R_{30} and X_9 to X_{12} are as defined under formula I, is explained in the following reaction scheme 8.

Reaction scheme 8:

According to reaction scheme 8, the pyrrolindione derivatives of formula Ie and the tetrahydroisindolindione derivatives of formula If can be obtained in a manner analogous to known methods, for example by reacting an anhydride of formula XXVIII (variant a)) and/or XXVIIIa (variant b)) with an aminopyridine of formula VI in an inert solvent, such as ether, for example dioxan, or a lower alkylcarboxylic acid, for example propionic acid, at temperatures of 20-200°C.


The compounds of formulae Ie and If (X_9 to $X_{12} = O$) which are obtainable according to reaction scheme 8 can be thionized if necessary with a suitable sulfur reagent (X_9 to $X_{12} = S$).

The preparation of a compound of formula li




wherein R_1 , R_2 , R_3 , R_{36} , R_{37} , X_{17} , and X_{18} are as defined under formula I, is explained in the following reaction scheme 9.


Reaction scheme 9:



According to reaction scheme 9, compounds of formula II can be prepared by known methods, for example by first reacting a carbamate of formula VIIIc (variant a)) and/or an isothiocyanate of formula IXc (variant b)) with a hydrazine derivative of formula XXIX to form the semicarbazide derivative of formula XXX, and then cyclizing this derivative in the presence of a carbonylation or thiocarbonylation reagent of formula XXXI. Both reaction steps are usefully accomplished in a suitable solvent and in the presence of a base. A suitable (thio)carbonylation reagent of formula XXXI is for example phosgene, diphosgene, thiophosgene or carbonyldiimidazol. L_3 in a compound of formula XXXI is therefore a leaving group such as a halogen, for example, chlorine or bromine, trichloromethoxy or




The preparation of a compound of formula Ik



(Ik),

wherein R_1 , R_2 , R_3 , R_{38} , R_{39} , and X_{19} are as defined under formula I, is explained in the following reaction scheme 10.

Reaction scheme 10:













According to reaction scheme 10, the triazolone derivatives of formula Ik can be prepared in a manner analogous to known methods, starting for example from the hydrazinopyridine derivative of formula XIV, which according to variant a) is usefully reacted with a keto acid of formula XXXII in the presence of an acid catalyst, such as a lower alkylcarboxylic acid, for example propionic acid, a mineral acid, for example sulfuric acid or hydrochloric acid, or a sulfonic acid, for example p-toluenesulfonic acid, to form a hydrazone derivative of formula XXXIII. This can subsequently be cyclized with an azide of formula XXXIV to form a triazolone derivative of formula Ik, wherein X_{19} is oxygen, and R_{38} is hydrogen, and then further derivatized if necessary according to standard methods using an alkylation reagent of formula XXXV or a sulfur reagent.

According to variant b), the hydrazinopyridine derivative of formula XIV can be cyclized with an iminoether of formula XXXVI to form a triazolone derivative of formula Ik, wherein X_{19} is oxygen, and R_{38} is hydrogen, and then if necessary alkylated or thionized as described under variant a).

According to variant c) in reaction scheme 10, the hydrazinopyridine derivative of formula XIV can be reacted first with an aldehyde of formula XXXVII and then, in the presence of a lower alkylcarboxylic acid, such as acetic acid, with an alkali metal cyanate to form a


compound of formula XXXVIII which, if necessary, is not isolated, and finally cyclized with an oxidizing agent, such as alkali metal hypochlorite (Javelle) to form a compound of formula Ik, wherein X_{19} is oxygen, and R_{38} is hydrogen. If necessary, the resulting compound of formula Ik can be alkylated or thionized, as described under variant a).

In certain cases, compounds of formula I can also be usefully obtained in a manner analogous to that described in J. Het. Chem. 15, 1221 (1978) by the substitution of a 2-halogen pyridine of formula III (L_4 =halogen), if necessary in the presence of a suitable solvent and a base, with the desired heterocycles of formulae W_{01} to W_{010}




a compound of formula Ic in reaction scheme 11.

Reaction scheme 11:




The intermediate products of formula II



wherein R₁ and R₂ are as defined under formula I, L₄ is a leaving group, such as halogen or C₁-C₄alkyl or phenylsulfonyl, and W is a W₃, W₄, W₅, W₆, W₉ or W₁₀ group, are new. The invention thus also relates to these compounds.

The preparation of compounds of formula II is explained in reaction scheme 12.

Reaction scheme 12:

The pyridin-N-oxides of formula XXXX (reaction scheme 12) can be prepared according to known methods, such as described in Org. Synth. 4, 828 (1963); *ibid.* 3, 619 (1955); US-A-3 047 579; and B. Iddon and H. Suschitzky in "Polychloroaromatic Compounds", Editor H. Suschitzky, Plenum Press, London 1974, page 197, a useful method being to react the pyridine derivatives of formula XXXIX with oxidizing agents, such as organic peroxy acids, for example m-chloroperbenzoic acid, peracetic acid and pertrifluoroacetic acid, or aqueous hydrogen peroxide solution or hydrogen peroxide urea adduct together with carboxylic acids and/or carboxylic acid anhydrides, or inorganic peroxy acids, for example peroxymonosulfuric acid (Caro's acid).


Suitable solvents are, for example, water, organic acids such as acetic acid and trifluoroacetic acid, halogenated hydrocarbons such as dichloromethane and 1,2-dichloroethane, esters such as ethyl acetate, ethers such as tetrahydrofuran and dioxan or mixtures comprising these solvents. The reaction temperatures lie within the range of -20°C to 100°C , depending on the solvent or solvent mixture used.

The pyridin-N-oxides of formula XXXX can be halogenated either directly according to known methods, for example with phosphorus oxychloride, phosphorus oxybromide, sulfuryl chloride, thionyl chloride or phosphorus pentachloride in phosphorus oxychloride to form the halogen pyridine derivatives of formula II ($L_4 = \text{halogen}$), or first reacted – likewise according to known methods (e.g. Quart. Rev. 10, 395 (1956); J. Am. Chem. Soc. 85, 958 (1963); and J. Org. Chem. 26, 428 (1961)) – in the presence of anhydrides, for example acetic anhydride, trifluoroacetic anhydride and methanesulfonic acid anhydride in a suitable inert solvent, such as halogenated hydrocarbons, for example dichloromethane and 1,2-dichloroethane, amides such as N,N-dimethylformamide and 1-methyl-2-pyrrolidone and if

necessary in the presence of sodium acetate, to form the pyridol derivatives of formula XXXXI, which can then be halogenated to form halogen pyridines of formula II, as described above for compounds of formula XXXX (L_4 = halogen).

The reaction temperatures for this transformation reaction generally lie within the range of -30°C to 80°C . By analogy with Tetrahedron 37, 187 (1981), antimony pentachloride (Katada reaction) presents itself as a further variant for the above transformation reaction.

The method described in the invention for the preparation of compounds of formula II



wherein R_1 and R_2 are as defined under formula I, W is a W_1 to W_{10} group, and L_4 is a C_1 - C_4 alkyl or phenylsulfonyl group, is carried out starting from a compound of formula II, wherein R_1 , R_2 and W have the meanings indicated and L_4 is halogen, by means of reaction with a C_1 - C_4 alkyl or phenyl thiol in the presence of a suitable base, followed by oxidation of the resulting thioether with an oxidizing agent such as hydrogen peroxide or *m*-chloroperbenzoic acid.

The starting compounds of formula XXXIX used in reaction scheme 12 can be prepared in a manner analogous to the methods described for compounds of formula Ia to Ik (R_3 =hydrogen) under reaction schemes 2 to 11.

The compounds of formulae III and VI are known or can be prepared according to known methods, as described in DE-A-3 917 469; WO 97/07114;

WO 92/00976; JP-A-58-213 776; EP-A-0 012 117; EP-A-0 306 547; EP-A-0 030 215; EP-A-0 272 824; EP-A-0 500 209; US-A-4 996 323; US-A-5 017 705; WO 97/05112; J. Het. Chem. 11, 889 (1974); J. Het. Chem 21, 97 (1984); Tetrahedron 41, 4057 (1985); Heterocycles 22,117; Synth. 1988, 938; J. Med. Chem. 25, 96.

The 2-aminopyridines of formula VI can in addition be prepared by Curtius, Hofmann or Lossen reactions from corresponding pyridine derivatives with carboxylic acid, carboxylic acid chloride, carboxylic acid azide, carboxylic acid ester or carboxylic acid amide functions in Position 2.

The reagents of formulae V, VII, X, XII, XIII, XV, XVa, XVI, XVIII, XIX, XXI, XXII, XXIVa, XXIVb, XXV, XXVa, XXVb, XXVc, XXXIV, XXVIII, XXVIIIa, XXIX, XXXI, XXXII, XXXIV,

XXXV, XXXVI and XXXVII as used in reaction schemes 1 to 10 are either known or can be prepared in a manner analogous to disclosed methods.

The heterocycles of formulae W_{01} to W_{010} are either known or can be prepared in a manner analogous to known standard methods of heterocyclic chemistry.

The reactions for obtaining the compounds of formula I are advantageously carried out in aprotic inert organic solvents. Such solvents are hydrocarbons such as benzene, toluene, xylene or cyclohexane, chlorinated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane or chlorobenzene, ethers, including diethyl ether, 1,2-dimethoxyethane, diglyme, tetrahydrofuran or dioxane, nitriles such as acetonitrile or propionitrile, amides such as N,N-dimethyl formamide, diethyl formamide or N-methylpyrrolidinone. The reaction temperatures are preferably in the range from -20° to $+120^{\circ}\text{C}$. The reactions are usually slightly exothermic and can as a rule be carried out at room temperature. The reaction mixture can be heated for a brief time to boiling point to shorten the reaction time or also to initiate the reaction. The reaction times can also be shortened by addition of a few drops of a base as reaction catalyst. Particularly suitable bases are tertiary amines such as trimethylamine, triethylamine, quinuclidine, 1,4-diazabicyclo[2.2.2]octane, 1,5-diazabicyclo[4.3.0]non-5-ene or 1,5-diazabicyclo[5.4.0]undec-7-ene. Further suitable bases are also inorganic bases, typically hydrides such as sodium or calcium hydride, hydroxides such as sodium and potassium hydroxide, carbonates such as sodium and potassium carbonate, or hydrogencarbonates such as potassium and sodium hydrogencarbonate.

The compounds of formula I can be isolated in conventional manner by concentrating the reaction mixture and/or removing the solvent by evaporation and by recrystallizing or triturating the solid residue in a solvent in which it is not readily soluble, typically an ether, an aromatic hydrocarbon or a chlorinated hydrocarbon, or by means of column chromatography and a suitable eluent.

The compounds of formula I or compositions containing them may be used according to this invention by all standard methods of application used in agriculture, including preemergence application, postemergence application and seed dressing, as well as by different methods and techniques such as controlled release. For controlled release, a solution of the herbicide is applied to mineral granular carriers or to polymerized granules (urea/formaldehyde) and then dried. A coating can then be additionally applied (coated

granules) that allows the herbicide to be released at a controlled rate over a specific period of time.

The compounds of formula I may be used as herbicides in unmodified form, i.e. as obtained in the synthesis. Preferably they are processed in conventional manner with the auxiliary agents customarily employed in formulation technology, e.g. to emulsifiable concentrates, directly sprayable or dilutable solutions, dilute emulsions, wettable powders, soluble powders, dusts, granulates or microcapsules. Such formulations are described, for example, in WO 97/34485 on pages 9 to 13. As with the type of agents, the methods of application such as spraying, atomizing, dusting, wetting, scattering or pouring, are selected in accordance with the intended objectives and the prevailing circumstances.

The formulations, i.e. the agents, preparations, or compositions containing the compound of formula I or at least one compound of formula I and usually one or more than one liquid or solid formulation assistant, are prepared in known manner, e.g. by homogeneously mixing and/or grinding the herbicide with said formulation auxiliaries, typically solvents or solid carriers. Surface-active compounds (surfactants) may additionally be used for preparing the formulations. Examples of solvents and solid carriers are described in WO 97/34485 on page 6.

Depending on the herbicide of formula I to be formulated, suitable surface-active compounds are nonionic, cationic and/or anionic surfactants and surfactant mixtures having good emulsifying, dispersing and wetting properties.

Examples of suitable anionic, non-ionic, and cationic surfactants are listed in WO 97/34485 on pages 7 and 8.

Also the surfactants customarily employed in the art of formulation and described, *inter alia*, in "McCutcheon's Detergents and Emulsifiers Annual" MC Publishing Corp., Ridgewood New Jersey, 1981, Stache, H., "Tensid-Taschenbuch" (Handbook of Surfactants), Carl Hanser Verlag, Munich/Vienna, 1981, and M. and J. Ash, "Encyclopedia of Surfactants", Vol I-III, Chemical Publishing Co., New York, 1980-81 are suitable for manufacture of the herbicides according to the invention.

The herbicidal compositions will as a rule contain from 0.1 to 99 % by weight, preferably from 0.1 to 95% by weight, of herbicide, from 1 to 99.9% by weight, preferably from 5 to 99.8 % by weight, of a solid or liquid adjuvant, and from 0 to 25% by weight, preferably from 0.1 to 25% by weight, of a surfactant. Whereas it is preferred to formulate commercial products as concentrates, the end user will normally use dilute formulations. The compositions may also contain further ingredients, such as: stabilisers, e.g. where appropriate epoxidized vegetable oils (epoxidized coconut oil, rapeseed oil, or soybean oil);

antifoams, typically silicone oil; preservatives; viscosity regulators; binders; and tackifiers; as well as fertilizers or other chemical agents.


The compounds of formula I are usually applied with success to the plants or the locus thereof in concentrations of 0.001 to 4 kg/ha, especially 0.005 to 2 kg/ha. The concentration required to achieve the desired action can be determined by experimentation. It will depend on the type of action, the development stage of the cultivated plant and of the weed, as well as on the application (locus, time, method), and as a result of these variables can vary over a wide range.

The compounds of formula I have excellent herbicidal and growth inhibiting properties, which make them suitable for application in crops of cultivated plants, especially in cereals, cotton, soybeans, sugar beet, sugar cane, plantations, rape, maize, and rice, and for the non-selective control of weeds. Crops will also be understood as meaning those crops that have been made tolerant to herbicides or classes of herbicides by conventional breeding or genetic engineering methods. The weeds to be controlled may be monocot as well as dicot weeds, typically *Stellaria*, *Nasturtium*, *Agrostis*, *Digitaria*, *Avena*, *Setaria*, *Sinapis*, *Lolium*, *Solanum*, *Echinochloa*, *Scirpus*, *Monochoria*, *Sagittaria*, *Bromus*, *Alopecurus*, *Sorghum halepense*, *Rottboellia*, *Cyperus*, *Abutilon*, *Sida*, *Xanthium*, *Amaranthus*, *Chenopodium*, *Ipomoea*, *Chrysanthemum*, *Galium*, *Viola*, and *Veronica*.

The invention is illustrated by the following non-limitative Examples.


Preparative Examples:

Example H1: Preparation of 2-N-ethoxycarbonylamino-3-fluoro-5-chloropyridine




294 g 2-Amino-3-fluoro-5-chloropyridine is dissolved in 1 l dry pyridine and cooled to 0°C, then 220 g ethyl chloroformate is stirred in drop by drop and stirring continued at 22°C until the reaction is complete. The reaction mixture is then poured onto ice water, adjusted to pH 4-5 with 2N hydrochloric acid and extracted with ethyl acetate. The combined extracts are washed with water, dried over sodium sulfate, concentrated by evaporation and crystallized by the addition of n-hexane. The precipitate obtained is filtered off, washed with n-hexane and dried in a vacuum. The title compound is obtained with a melting point of 132°C.

Example H2: Preparation of 1-(3-fluoro-5-chloropyridin-2-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione



Under a nitrogen atmosphere, while cooling and stirring, a solution of 22.7 g 4,4,4-trifluoro-3-amino-2-butenic acid ethyl ester is added dropwise to 5.1 g of a sodium hydride dispersion (60%) in 60 ml N-methylpyrrolidine at 0–5°C and stirred at 22°C until hydrogen evolution is complete. Then 23.7 g 2-ethoxycarbonylamino-3-fluoro-5-chloropyridine (Example H1) is added and the reaction mixture heated for about 5 hours to 120°C. The mixture is then cooled, 16.7 g methyl iodide is added dropwise and stirring is continued overnight at 22°C. After the reaction mixture has been taken up in ethyl acetate, it is washed with ice water, dried over sodium sulfate, filtered, and concentrated by evaporation. The residue obtained is recrystallized from ethyl acetate / n-hexane. The title compound is obtained with a melting point of 133–134°C.


Example H3: Preparation of 1-(3-fluoro-5-chloro-2-pyridyl-N-oxide)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione



24 g 1-(3-Fluoro-5-chloropyridin-2-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H2) in 150 ml dichloromethane is cooled to -5°C, and 2 g hydrogen peroxide-urea adduct is added. Then 2.7 ml trifluoroacetic acid anhydride, dissolved in 2 ml dichloromethane, is added dropwise and the reaction mixture is stirred overnight after the exothermic reaction has subsided. Within 3 hours another 5 g of hydrogen peroxide-urea adduct and 3 ml trifluoroacetic acid anhydride are added in 2 portions and, after the exothermic reaction has subsided, the mixture is heated to 25–35°C until the reaction is complete. The mixture is then cooled and, at -5°C, is adjusted to pH 7.5 first with 2N sodium hydroxide solution, then with saturated sodium hydrogencarbonate solution, distributed between dichloromethane and ice water, and the separated organic phase dried over sodium sulfate, filtered and concentrated by evaporation. The remaining solid residue is


recrystallized from ethyl acetate / n-hexane. The desired title compound is obtained with a melting point of 142-143°C.

Example H4: Preparation of 1-(3-fluoro-5,6-dichloro-2-pyridyl)-3-methyl-4-trifluoromethyl-pyrimidin-2,6-dione



To a solution of 2.4 ml phosphorus oxytrichloride in 20 ml 1,2-dichloroethane, heated to 70°C, portions of 6.8 g 1-(3-fluoro-5-chloro-2-pyridyl-N-oxide)-3-methyl-4-trifluoromethyl-pyrimidin-2,6-dione (Example H3) are added, maintained at this temperature overnight, before a further 4.0 ml phosphorus oxytrichloride is added and heated for 20 hours. The mixture is then cooled, poured over ice water, extracted with dichloroethane, and the combined extracts are washed with 2N sodium hydroxide solution and water, dried over sodium sulfate and evaporated by concentration. The residue is purified by means of silica gel chromatography (eluent: hexane / ethyl acetate 9 / 1). The title compound is obtained with a melting point of 113-115°C.

Example H5: Preparation of 1-(2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione




To a solution of 29.6 g 1-(3-fluoro-5-chloro-2-pyridyl-N-oxide)-3-methyl-4-trifluoromethyl-pyrimidin-2,6-dione (Example H3) in 400 ml dimethylformamide, cooled to -30°C, 182 g trifluoroacetic acid anhydride is added dropwise, and the mixture is then stirred overnight at -30°C, and on the next day at 22°C. In a vacuum, the mixture is then liberated from surplus trifluoroacetic acid anhydride, cooled to -5°C and carefully neutralized first with diluted sodium hydroxide solution and then with sodium hydrogencarbonate solution. After the addition of ice water, the mixture is extracted with ethyl acetate, and the combined extracts are washed with water and dried over sodium sulfate. This is then filtered, the filtrate

concentrated by evaporation and the resulting residue purified over a silica gel column (eluent: n-hexane / ethyl acetate 8 / 2) with an ascending gradient in respect of ethyl acetate. The title compound is obtained with a melting point of 200-202°C.

In addition, a fraction is obtained which, besides 1-(2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione, comprises also the isomer 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione. The latter isomeric compound is obtained by a further rearrangement reaction. The ratio of the two isomers 1-(2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione varies (at approx. 3 : 1) depending on reaction conditions.


The isomeric mixture of the fraction can either be used directly for the next reaction step or separated by means of HPLC (Li-Chrospher Si60; eluent: ethyl acetate / hexane 15 / 85 to 30 / 70, ascending gradient of ethyl acetate). Pure 1-(3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione is obtained with a melting point of 189–192°C.

Example H6: Preparation of 1-(6-Ethoxycarbonyl-5-chloro-3-fluoropyridin-2-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione



A mixture of 4 g 1-(3-fluoro-5,6-dichloro-2-pyridyl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H4), 3.4 g triethylamine and 2 g dichloro-bis(triphenylphosphine)palladium in 50 ml ethanol is pressurized in an autoclave with carbon monoxide at 180 bar and the mixture heated for about 30 hours to 101°C, leading to a pressure build-up of max. 228 bar. The heating is then switched off, the reaction mixture left to stand at 22°C over the weekend and filtered; the filtrate is then concentrated by evaporation in a vacuum, and the residue obtained is purified over a silica gel column (eluent: n-hexane / ethyl acetate 9 / 1). The desired title compound is obtained as a yellowish resin;

Example H7: Preparation of 1-(2-trifluoromethyl-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione




To a solution of 0.848 g of a mixture of 2-hydroxy-3-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 3-hydroxy-2-chloro-5-fluoropyridin-6-yl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione (Example H5), 0.938 g triphenylphosphine, 0.22 ml 2,2,2-trifluoroethanol and 0.58 ml diethylazodicarboxylate are added at 22°C, and the mixture is stirred for 14 hours at 22°C. The same quantities of triphenylphosphine, diethylazodicarboxylate and trifluoroethanol are added and the mixture is stirred for a further 4 hours. Ice water is then added, distributed between dichloromethane and water, the extracts washed with water, dried and concentrated by evaporation. The residue is first filtered via silica gel (hexane / ethyl acetate 2 / 1) and then separated by means of HPLC (Li-chrospher Si 60; hexane-ethyl acetate 15-30%, ascending gradient).

After the separation of 1-(2-trifluoroethoxy-3-chloro-5-fluoro-6-pyridyl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione and 1-(3-trifluoroethoxy-2-chloro-5-fluoro-6-pyridyl)-3-methyl-4-trifluoromethylpyrimidin-2,6-dione, the desired title compound is obtained with a melting point of 112–113°C.

By analogy, these and analogous trifluoromethyl compounds are obtainable as described in JP-A-58 206 563 or by the reaction of corresponding carboxylic acid derivatives with sulfur tetrafluoride or by the reaction of corresponding trichloromethyl compounds with hydrogen fluoride.


Example H8: Preparation of tetrahydroimidazo[1,5-a]pyridin-1,3-dione



A reaction vessel containing 260 ml water is prepared with 34.6 g (0.193 mol) 2-piperidine-carboxylic acid methyl ester · hydrochloride, to which 17.4 g (0.216 mol) potassium cyanate is then added. Then 30 ml glacial acetic acid is added and the resulting homogeneous solution is stirred for 4.5 hours at 22°C. The reaction solution is subsequently saturated with saline (NaCl) and extracted twice with 200 ml tert-butyl methyl ether each time. The organic fractions are combined, dried over sodium sulfate and concentrated. As residue, 11 g of a viscous oil is obtained, from which crystals precipitate out overnight. Decanting off the


remaining oil enables the crystals to be separated off and isolated by trituration (digestion) in diethyl ether. The desired title compound is obtained with a melting point of 122-123°C in a yield of 5.75 g.

Example H9: Preparation of 2-(3-fluoro-6-chloro-5-cyano-2-pyridyl)tetrahydroimidazo[1,5-a]pyridin-1,3-dione



A reaction vessel is prepared with 0.77 g (0.005 mol) of the hydantoin derivative from Example H8 in 50 ml acetonitrile. To this solution, 0.95 g (0.00688 mol) finely pulverized potassium carbonate and 0.96 g (0.00503 mol) 2,6-dichloro-3-cyano-4-fluoropyridine are added consecutively, and the mixture is stirred and heated to reflux temperature for 5 hours. At the end of this time, no further starting compound is detectable (TLC analysis). The reaction mixture is cooled, filtered, and the solvent evaporated off. The dark brown, viscous oil obtained is chromatographed under pressure over a silica gel column (30 g) (eluent: hexane / ethyl acetate 2 / 1). The fractions comprising product with an R_f value of 0.26 are combined and liberated from the solvent. The desired product is obtained as white crystals with a melting point of 192–193°C. MS (FD): $[M^+]$, 40%] 308.

Example H10: Preparation of 2-(5-chloro-3-fluoropyridin-2-yl)-7-hydroxytetrahydroimidazo-(1.5-a)-pyridin-1,3-dione



A reaction mixture comprising 100 ml dioxan, 50 ml N,N-dimethylformamide, 8 ml propylene oxide, 6 ml 1.8-diazabicyclo-(5.4.0)-undec-7-en and 8.0 g 4-hydroxypiperidine-2-carboxylic acid ethyl ester • hydrochloride is stirred overnight at 20°C. Then 4.4 g potassium tert-butylate and 50 ml N,N-dimethylformamide are added and the resulting suspension is heated for about 4 hours to 95°C. The reaction mixture is then cooled, adjusted to pH 6.5–7.0 with cold, aqueous 2N hydrochloric acid solution and extracted with ethyl acetate. The combined extracts are washed with saline solution and water, concentrated by evaporation and the solid residue purified by means of silica gel chromatography (eluent: hexane / ethyl

acetate). The title compound is obtained as a mixture of two separable diastereomers with a melting point of 183–185°C and 184–186°C.

Example H11: Preparation of 2-(5-Chloro-3-fluoro-pyridine-2-yl)-7-fluoro-tetrahydroimidazo-(1.5-a)-pyridine-1,3-dione

2.6 g of 2-(5-Chloro-3-fluoro-pyridine-2-yl)-7-hydroxi-tetrahydroimidazo-(1.5-a)-pyridine-1,3-dione (isomer B) in 80 ml dichlorromethane is treated at – 55°C - -65°C with 1.9 ml of diethylaminosulfur trifluoride (DAST) and stirred at the same temperature for 1 hr. The vessel is then allowed to stir at room temperature over night. The resulting brownish solution is treated with ice and water and extracted with ethyl acetate. The extracts are washed with water, dried, filtered through a small silicagel column and evaporated to give the desired product with m.p. 154-157°C.

Example H12: Preparation of 2-(6-ethoxycarbonyl-5-chloro-3-fluoro-pyridin-2-yl)-5-trifluoromethyl-2.H.-pyridazin-3-one (compound 35.004)

A mixture of 1.7 g 2-(5,6-dichloro-3-fluoropyridin-2yl)-5-trifluoromethyl-2.H.-pyridazin-3-one, 1g of bis-(triphenylphosphine)-palladium(II)-dichloride, and 2.3 ml triethylamine in 35 ml ethanol was placed in an autoclave and heated under a pressure of 180-235 bar of carbon monoxide at 100°C for 24 hrs. Then, the reaction mixture was cooled down, filtered and evaporated. Purification of the residue by HPLC-chromatography (ethyl acetate-hexane) led to the desired product. ¹H-NMR (CDCl₃): 8.11 ppm (s, 1H); 7.80 ppm (d, 1H); 7.35 ppm (s, 1H); 4.46 ppm (q, 2H); 1.41 ppm (t, 3H).

In an analogous manner, 2-(6-ethoxycarbonyl-5-chloro-3-fluoro-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2.H.-pyridazin-3-one (39.004) was obtained.

Example H13: Preparation of 2-(5,6-dichloro-3-fluoro-pyridin)-2-yl-4-methyl-5-trifluoromethyl-2.H.-pyridazine-3-one

A mixture of 1.6g 2-(5-chloro-3-fluoro-1-oxy-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one and 2 ml of phenyl dichlorophosphate was heated in a sealed tube at 140°C for 3 hrs. The reaction was then cooled, poured into ice and water, neutralised with aqueous sodium hydrogen carbonate, extracted with ethyl acetate, washed with water and dried over sodium sulfate. After dilution with hexane, the extract was filtered through silicagel and evaporated to give the desired product with m.p. 96-98°C.

Example H14: Preparation of 2-(5-chloro-3-fluoro-1-oxy-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one (compound 625.001)

5.01 g of 2-(5-chloro-3-fluoro-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one in 150 ml of 1,2-dichloroethane was treated at 0°C with 2.1g hydrogen peroxide-urea adduct and 2.7 ml of trifluoroacetic anhydride and allowed to stir at 20°C until conversion was complete. Then the solution was poured into ice and water, neutralised with aqueous sodium hydrogen carbonate and extracted with dichloromethane. The extracts were combined, washed with water, dried, filtered and evaporated to give the desired product with m.p. 140-143°C.

Example H15: Preparation of 2-(5-chloro-3-fluoro-pyridin-2-yl)-4-methyl-5-trifluoromethyl-2H-pyridazin-3-one (608.001)

A solution of 8.09g 3-((5-chloro-3-fluoro-pyridine-2-yl) -hydrazono)-1,1,1-trifluoro-propan-2-one and 11.5 g 1-carbomethoxyethylidene triphenylphosphine in 200 ml dioxane was stirred for 30 min. at 20 °C and then heated until complete conversion at 50°C. The reaction mixture was diluted with hexane, filtered from solid triphenylphosphine oxide through silicagel and evaporated. Further purification of the residue on silicagel (ethyl acetate-hexane 3:7) led to the desired product with m.p. 91-93°C.


Example H16: Preparation of 3-((5-chloro-3-fluoro-pyridin-2-yl) -hydrazono)-1,1,1-trifluoro-propan-2-one (intermediate)

6.75 g 1,1-dibromo-3,3,3-trifluoroacetone were stirred for 30 min. at 80°C in a solution of 9.0g sodium acetate in 250 ml water. Then the solution was cooled at 0°C and 4.0 g 2-hydrazino-3-fluoro-5-chloropyridin were added.. Stirring was continued for 3.5 hrs. Then the reaction mixture was extracted with ethyl acetate, the extracts were washed with water and dried. After evaporation, the remaining residue was purified on silcagel (hexane-ethyl acetate 8:2) to give the title compound as brownish residue which was directly used for the next step. MS: (M-H)=268.

In analogous manner, 3-((6-chloro-5-cyano-3-fluoro-pyridin-2-yl) -hydrazono)-1,1,1-trifluoro-propan-2-one with m.p. 174-176°C was obtained.


The preferred compounds listed in the following tables can also be obtained in an analogous manner and according to the methods illustrated in the general reaction schemes 1-11 and described in the cited references.

Table 1: A preferred group of compounds of formula I corresponds to the general formula




A, constituting the disclosure of 448 specific compounds of formula I₁.

Table 2: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂.

Table 3: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃.

Table 4: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄.

Table 5: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₅.

Table 6: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₆.

Table 7: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇.

Table 8: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₈.

Table 9: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉.

Table 10: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀.

Table 11: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁.

Table 12: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂.

Table 13: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃.

Table 14: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄.

Table 15: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅.

Table 16: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆.

Table 17: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇.

Table 18: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈.

Table 19: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉.

Table 20: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀.

Table 21: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁.

Table 22: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂.

Table 23: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₃

Table 24: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₄.

Table 25: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₅.

Table 26: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₆.

Table 27: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₇.

Table 28: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₈.

Table 29: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₉.

Table 30: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₀.

Table 31: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₁.

Table 32: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₂.

Table 33: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₃.

Table 34: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₄.

Table 35: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₅.

Table 36: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₃₆.

Table 37: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₇.

Table 38: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₈.

Table 39: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₃₉.

Table 40: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₄₀.

Table 41: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₄₁.

Table 42: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₄₂.

Table 43: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₄₃.

Table 44: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₄₄.

Table 45: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₄₅.

Table 46: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₄₆.

Table 47: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₄₇.

Table 48: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₄₈.

Table 49: A further preferred group of compounds of formula I corresponds to the general





Table A, constituting the disclosure of 448 specific compounds of formula I₄₉.

Table 50: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₅₀.

Table 51: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₁.

Table 52: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₂.

Table 53: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₃.

Table 54: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₄.

Table 55: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₅

Table 56: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₆.

Table 57: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₇

Table 58: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₅₈.

Table 59: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₅₉.

Table 60: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₆₀.

Table 61: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₆₁.

Table 62: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₆₂.

Table 63: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₃.

Table 64: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₄.

Table 65: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₅.

Table 66: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₆.

Table 67: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₇.

Table 68: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₈.

Table 69: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₆₉.

Table 70: A further preferred group of compounds of formula I corresponds to the general





Table A, constituting the disclosure of 448 specific compounds of formula I₇₀.

Table 71: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₁.

Table 72: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₇₂.

Table 73: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₇₃.

Table 74: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₇₄.

Table 75: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₇₅.

Table 76: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₇₆.

Table 77: A further preferred group of compounds of formula I corresponds to the general





Table A, constituting the disclosure of 448 specific compounds of formula I₇₇.

Table 78: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₇₈.

Table 79: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₇₉.

Table 80: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₀.

Table 81: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₈₁.

Table 82: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₈₂

Table 83: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₈₃.

Table 84: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₄

Table 85: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₅

Table 86: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₆.

Table 87: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₇.

Table 88: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₈.

Table 89: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₈₉.

Table 90: A further preferred group of compounds of formula I corresponds to the general





Table A, constituting the disclosure of 448 specific compounds of formula I₉₀.

Table 91: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₁.

Table 92: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₉₂.

Table 93: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₉₃.

Table 94: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₉₄.

Table 95: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₉₅.

Table 96: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₆.

Table 97: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₉₇.

Table 98: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₈.

Table 99: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₉₉.

Table 100: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₀.

Table 101: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₁.

Table 102: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₂.

Table 103: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₃.

Table 104: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₄.

Table 105: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₅.

Table 106: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₆.

Table 107: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₇.

Table 108: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₈.

Table 109: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₀₉.

Table 110: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₀.

Table 111: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₁.

Table 112: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₂.

Table 113: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₃.

Table 114: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₄.

Table 115: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₅.

Table 116: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₆.

Table 117: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₇.

Table 118: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₈.

Table 119: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₁₉.

Table 120: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₀.

Table 121: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₁.

Table 122: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₂.

Table 123: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₃.

Table 124: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₄.

Table 125: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₅.

Table 126: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₆.

Table 127: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₇.

Table 128: A further preferred group of compounds of formula I corresponds to the general




are defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₈.

Table 129: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₂₉.

Table 130: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₀.

Table 131: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₁.

Table 132: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₂.

Table 133: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₃.

Table 134: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₄.

Table 135: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₅.

Table 136: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₆.

Table 137: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₇.

Table 138: A further preferred group of compounds of formula I corresponds to the general




Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₈.

Table 139: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₁₃₉.

Table 140: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₀.

Table 141: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₁.

Table 142: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₂.

Table 143: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₃.

Table 144: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₄.

Table 145: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₅.

Table 146: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₆.

Table 147: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₇.

Table 148: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₈.

Table 149: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₄₉.

Table 150: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₀.

Table 151: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₁.

Table 152: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₂.

Table 153: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₃.

Table 154: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₄.

Table 155: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₅.

Table 156: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₆.

Table 157: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₇.

Table 158: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₈.

Table 159: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₅₉.

Table 160: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₀.

Table 161: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₁.

Table 162: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₂.

Table 163: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₃.

Table 164: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₄.

Table 165: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₅.

Table 166: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₆.

Table 167: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₇.

Table 168: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₈.

Table 169: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₆₉.

Table 170: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₀.

Table 171: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₁.

Table 172: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₂.

Table 173: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₃.

Table 174: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₄.

Table 175: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₅.

Table 176: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₆.

Table 177: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₇.

Table 178: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₈.

Table 179: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₇₉.

Table 180: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₀.

Table 181: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₁.

Table 182: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₂.

Table 183: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₃.

Table 184: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₄.

Table 185: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₅.

Table 186: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₆.

Table 187: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₇.

Table 188: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₈.

Table 189: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₈₉.

Table 190: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₀.

Table 191: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₁.

Table 192: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₂.

Table 193: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₃.

Table 194: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₄.

Table 195: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₅.

Table 196: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₆.

Table 197: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₇.

Table 198: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₈.

Table 199: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₁₉₉.

Table 200: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₀.

Table 201: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₁.

Table 202: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₂.

Table 203: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₃.

Table 204: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₄.

Table 205: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₅.

Table 206: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₆.

Table 207: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₇.

Table 208: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₈.

Table 209: A further preferred group of compounds of formula I corresponds to the general



in Table A, constituting the disclosure of 448 specific compounds of formula I₂₀₉.

Table 210: A further preferred group of compounds of formula I corresponds to the general






Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₀.

Table 211: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₁.

Table 212: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₂.

Table 213: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₃.

Table 214: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₄.

Table 215: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₅.

Table 216: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₆.

Table 217: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₇.

Table 218: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₈.

Table 219: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₁₉.

Table 220: A further preferred group of compounds of formula I corresponds to the general




in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂₀.

Table 221: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂₁.

Table 222: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 448 specific compounds of formula I₂₂₂.

Table A

Cmpd no.	R ₁	R ₃
.001	F	CN
.002	F	CHO
.003	F	COCH ₃
.004	F	COOCH ₂ CH ₃
.005	F	COOCH ₂ C ₆ H ₅
.006	F	COCl
.007	F	COCH ₂ CH ₂ Cl
.008	F	COOH
.009	F	COOCH ₃
.010	F	COOCH ₂ CH ₃
.011	F	COOCH(CH ₃) ₂
.012	F	COOCH ₂ CH=CH ₂
.013	F	COO(CH ₂) ₅ CH ₃

Cmpd no.	R ₁	R ₃
.014	F	COOCH(CH ₃)CH=CH ₂
.015	F	COOCH ₂ (2-F-C ₆ H ₅)
.016	F	COOC ₆ H ₅
.017	F	COOCH ₂ CH ₂ OCH ₂ CH ₃
.018	F	COOCH(CH ₃)CH ₂ SCH ₃
.019	F	COO(oxetanyl)
.020	F	COOCH ₂ (oxiranyl)
.021	F	COO(cyclopentyl)
.022	F	COSCH ₃
.023	F	COSCH(CH ₃) ₂
.024	F	COSCH ₂ C ₆ H ₅
.025	F	CONH ₂
.026	F	CONH(CH ₂ CH=CH ₂)
.027	F	CONHCH ₂ C ₆ H ₅
.028	F	CON(CH ₂ CH=CH ₂) ₂
.029	F	CON(CH ₃)OCH ₃
.030	F	COOCH ₂ CH ₂ COOH
.031	F	COOCH(CH ₃)COOCH ₃
.032	F	COOCH(CH ₃)COOCH ₂ C ₆ H ₅
.033	F	COOCH(CH ₃)CH ₂ COOCH ₂ CH ₃
.034	F	(S)-COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.035	F	(R)-COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.036	F	COOCH(CH ₃)CH ₂ CONHCH ₂ CH ₃
.037	F	COOCH(CH ₃)CH ₂ CON(CH ₃) ₂
.038	F	(R)-COOCH(CH ₃)CH ₂ COOCH ₃
.039	F	COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.040	F	COOC(CH ₃) ₂ COCH ₃
.041	F	COOC(CH ₃) ₂ COOH
.042	F	COOC(CH ₃) ₂ COOCH ₃
.043	F	COOC(CH ₃) ₂ COOCH ₂ CH ₃
.044	F	COOC(CH ₃) ₂ COOCH(CH ₃) ₂
.045	F	COOC(CH ₃) ₂ COO(CH ₂) ₄ CH ₃
.046	F	COOC(CH ₃) ₂ COOCH ₂ C ₆ H ₅
.047	F	COOC(CH ₃) ₂ COOCH ₂ (2-F-C ₆ H ₅)
.048	F	COOC(CH ₃) ₂ COOCH ₂ CH=CH ₂
.049	F	(R)-COOCH(CH ₃)COOCH ₂ CH ₃
.050	F	COOC(CH ₃) ₂ COOCH ₂ C≡CH

Cmpd no.	R ₁	R ₃
.051	F	COO(CH ₃) ₂ COOCH ₂ CH ₂ OCH ₂ CH ₃
.052	F	COOC(CH ₃) ₂ COSCH ₃
.053	F	COOC(CH ₃) ₂ COSCH(CH ₃) ₂
.054	F	COOC(CH ₃) ₂ COSCH ₂ C ₆ H ₅
.055	F	COOC(CH ₃) ₂ CONH ₂
.056	F	COOC(CH ₃) ₂ CONHCH ₂ CH=CH ₂
.057	F	COOC(CH ₃) ₂ CON(CH ₂ CH ₃) ₂
.058	F	COOC(CH ₃) ₂ CON(CH ₃)CH ₂ CH ₂ OCH ₃
.059	F	COSCH(CH ₃)COOH
.060	F	COSCH(CH ₃)COOCH ₃
.061	F	COSCH(CH ₃)CONHCH ₂ CH=CH ₂
.062	F	CON(CH ₃)CH ₂ COOH
.063	F	CON(CH ₃)C(CH ₃) ₂ COOCH ₂ CH ₃
.064	F	CON(CH ₃)OCH ₂ COOCH ₃
.065	F	CON(CH ₃)OH
.066	F	CH ₃
.067	F	CH ₂ CH ₃
.068	F	CH(OH)CH ₃
.069	F	CH(OCH ₂ CH=CH ₂)CH ₃
.070	F	CH ₂ Cl
.071	F	CH ₂ OH
.072	F	CH ₂ OCOCH ₃
.073	F	CHClCH ₃
.074	F	CH ₂ CH ₂ CF ₃
.075	F	CH=CHCF ₃
.076	F	CH ₂ CH=CH ₂
.077	F	CH=CHCH ₃
.078	F	C≡CH
.079	F	CCCH ₂ OH
.080	F	CH ₂ CHClCOOH
.081	F	(R)-CH ₂ CHClCOOH
.082	F	(S)-CH ₂ CHClCOOH
.083	F	CH ₂ CH(CH ₃)COOH
.084	F	CH ₂ CH(CH ₃)COOCH ₂ CH ₃
.085	F	CH(Cl)CH ₂ COOCH ₃
.086	F	CH(Cl)C(Cl) ₂ COOH
.087	F	CH(Cl)CH(Cl)COOCH ₂ CH ₃

Cmpd no.	R ₁	R ₃
.088	F	CH ₂ CH(CH ₃)COOH
.089	F	CH ₂ CH(CH ₃)COCH ₂ CH=CH ₂
.090	F	CH ₂ CH(CH ₃)CONH(CH ₂ CH=CH ₂)
.091	F	CH ₂ CH(CH ₃)CON(CH ₃) ₂
.092	F	CH ₂ CH(CH ₃)COSCH(CH ₃) ₂
.093	F	CH ₂ CHClCOOC(CH ₃) ₃
.094	F	CH ₂ CHClCOOCH ₃
.095	F	CH ₂ CHClCOOCH ₂ CH ₃
.096	F	CH ₂ CHClCOOCH(CH ₃) ₂
.097	F	CH ₂ CHClCOOCH ₂ CH=CH ₂
.098	F	CH ₂ CHClCOOCH ₂ C ₆ H ₅
.099	F	CH ₂ CHClCOSCH ₃
.100	F	CH ₂ CHClCOSCH(CH ₃) ₂
.101	F	CH ₂ CHClCOSCH ₂ C ₆ H ₅
.102	F	CH ₂ CHClCONH ₂
.103	F	CH ₂ CHClCONH(CH ₂ CH=CH ₂)
.104	F	CH ₂ CHClCON(CH ₂ CH ₃) ₂
.105	F	CH ₂ CHClCONH(CH ₂ C ₆ H ₅)
.106	F	CH ₂ CHClCON(CH ₃)CH ₂ C ₆ H ₅
.107	F	CH=CHCOOH
.108	F	(E)-CH=CHCOOH
.109	F	(Z)-CH=CHCOOH
.110	F	CH=CHCOOCH ₃
.111	F	CH=CHCOOCH ₂ C ₆ H ₅
.112	F	CH=CHCONH ₂
.113	F	CH=CHCONH(CH ₂ CH=CH ₂)
.114	F	CH=C(Cl)COOH
.115	F	CH=C(Cl)CONH ₂
.116	F	CH=C(Cl)CONH(CH ₂ CH ₃)
.117	F	CH=C(Cl)CON(CH ₂ CH ₃) ₂
.118	F	CH=C(Cl)CONH(CH ₂ C ₆ H ₅)
.119	F	CH=C(Cl)COSCH ₃
.120	F	CH=C(Cl)COSCH(CH ₃) ₂
.121	F	CH=C(CH ₃)COOH
.122	F	CH=C(CH ₃)CONH(CH ₂ CH=CH ₂)
.123	F	CH=C(CH ₃)CON(CH ₃) ₂
.124	F	CH=C(CH ₃)COSCH ₂ CH ₃

Cmpd no.	R ₁	R ₃
.125	F	CH=C(CN)COOH
.126	F	CH=C(CN)COOC(CH ₃) ₃
.127	F	CH=C(CN)CON(CH ₂ CH=CH ₂) ₂
.128	F	CH=C(COOH) ₂
.129	F	CH=C(C ₆ H ₅)COOH
.130	F	CH=CHCH ₂ OH
.131	Cl	CN
.132	Cl	CHO
.133	Cl	COCH ₃
.134	Cl	COOCH ₂ CH ₃
.135	Cl	COOCH ₂ C ₆ H ₅
.136	Cl	COCl
.137	Cl	COCH ₂ CH ₂ Cl
.138	Cl	COOH
.139	Cl	COOCH ₃
.140	Cl	COOCH ₂ CH ₃
.141	Cl	COOCH(CH ₃) ₂
.142	Cl	COOCH ₂ CH=CH ₂
.143	Cl	COO(CH ₂) ₅ CH ₃
.144	Cl	COOCH(CH ₃)CH=CH ₂
.145	Cl	COOCH ₂ (2-F-C ₆ H ₅)
.146	Cl	COOC ₆ H ₅
.147	Cl	COOCH ₂ CH ₂ OCH ₂ CH ₃
.148	Cl	COOCH(CH ₃)CH ₂ SCH ₃
.149	Cl	COO(oxetanyl)
.150	Cl	COOCH ₂ (oxiranyl)
.151	Cl	COO(cyclopentyl)
.152	Cl	COSCH ₃
.153	Cl	COSCH(CH ₃) ₂
.154	Cl	COSCH ₂ C ₆ H ₅
.155	Cl	CONH ₂
.156	Cl	CONH(CH ₂ CH=CH ₂)
.157	Cl	CONHCH ₂ C ₆ H ₅
.158	Cl	CON(CH ₂ CH=CH ₂) ₂
.159	Cl	CON(CH ₃)OCH ₃
.160	Cl	COOCH ₂ CH ₂ COOH
.161	Cl	COOCH(CH ₃)COOCH ₃

Cmpd no.	R ₁	R ₃
.162	Cl	COOCH(CH ₃)COOCH ₂ C ₆ H ₅
.163	Cl	COOCH(CH ₃)CH ₂ COOCH ₂ CH ₃
.164	Cl	(S)-COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.165	Cl	(R)-COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.166	Cl	COOCH(CH ₃)CH ₂ CONHCH ₂ CH ₃
.167	Cl	COOCH(CH ₃)CH ₂ CON(CH ₃) ₂
.168	Cl	COOCH(CH ₃)CH ₂ COSCH ₂ CH ₃
.169	Cl	COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.170	Cl	COOC(CH ₃) ₂ COCH ₃
.171	Cl	COOC(CH ₃) ₂ COOH
.172	Cl	COOC(CH ₃) ₂ COOCH ₃
.173	Cl	COOC(CH ₃) ₂ COOCH ₂ CH ₃
.174	Cl	COOC(CH ₃) ₂ COOCH(CH ₃) ₂
.175	Cl	COOC(CH ₃) ₂ COO(CH ₂) ₄ CH ₃
.176	Cl	COOC(CH ₃) ₂ COOCH ₂ C ₆ H ₅
.177	Cl	COOC(CH ₃) ₂ COOCH ₂ (2-F-C ₆ H ₅)
.178	Cl	COOC(CH ₃) ₂ COOCH ₂ CH=CH ₂
.179	Cl	COOC(CH ₃) ₂ COOCH(CH ₃)CH=CH ₂
.180	Cl	COOC(CH ₃) ₂ COOCH ₂ C≡CH
.181	Cl	COO(CH ₃) ₂ COOCH ₂ CH ₂ OCH ₂ CH ₃
.182	Cl	COOC(CH ₃) ₂ COSCH ₃
.183	Cl	COOC(CH ₃) ₂ COSCH(CH ₃) ₂
.184	Cl	COOC(CH ₃) ₂ COSCH ₂ C ₆ H ₅
.185	Cl	COOC(CH ₃) ₂ CONH ₂
.186	Cl	COOC(CH ₃) ₂ CONHCH ₂ CH=CH ₂
.187	Cl	COOC(CH ₃) ₂ CON(CH ₂ CH ₃) ₂
.188	Cl	COOC(CH ₃) ₂ CON(CH ₃)CH ₂ CH ₂ OCH ₃
.189	Cl	COSCH(CH ₃)COOH
.190	Cl	COSCH(CH ₃)COOCH ₃
.191	Cl	COSCH(CH ₃)CONHCH ₂ CH=CH ₂
.192	Cl	CON(CH ₃)CH ₂ COOH
.193	Cl	CON(CH ₃)C(CH ₃) ₂ COOCH ₂ CH ₃
.194	Cl	CON(CH ₃)OCH ₂ COOCH ₃
.195	Cl	CON(CH ₃)OH
.196	Cl	CH ₃
.197	Cl	CH ₂ CH ₃
.198	Cl	CH(OH)CH ₃

Cmpd no.	R ₁	R ₃
.199	Cl	CH(OCH ₂ CH=CH ₂)CH ₃
.200	Cl	CH ₂ Cl
.201	Cl	CH ₂ OH
.202	Cl	CH ₂ OCOCH ₃
.203	Cl	CHClCH ₃
.204	Cl	CH ₂ CH ₂ CF ₃
.205	Cl	CH=CHCF ₃
.206	Cl	CH ₂ CH=CH ₂
.207	Cl	CH=CH(CH ₃)
.208	Cl	C≡CH
.209	Cl	C≡CCH ₂ OH
.210	Cl	CH ₂ CHClCOOH
.211	Cl	(R)-CH ₂ CHClCOOH
.212	Cl	(S)-CH ₂ CHClCOOH
.213	Cl	CH ₂ CH(CH ₃)COOH
.214	Cl	CH ₂ CH(CH ₃)COOCH ₂ CH ₃
.215	Cl	CH(Cl)CH ₂ COOCH ₃
.216	Cl	CH(Cl)C(Cl) ₂ COOH
.217	Cl	CH(Cl)CH(Cl)COOCH ₂ CH ₃
.218	Cl	CH ₂ CH(CH ₃)COOH
.219	Cl	CH ₂ CH(CH ₃)COCH ₂ CH=CH ₂
.220	Cl	CH ₂ CH(CH ₃)CONH(CH ₂ CH=CH ₂)
.221	Cl	CH ₂ CH(CH ₃)CON(CH ₃) ₂
.222	Cl	CH ₂ CH(CH ₃)COSCH(CH ₃) ₂
.223	Cl	CH ₂ CHClCOOC(CH ₃) ₃
.224	Cl	CH ₂ CHClCOOCH ₃
.225	Cl	CH ₂ CHClCOOCH ₂ CH ₃
.226	Cl	CH ₂ CHClCOOCH(CH ₃) ₂
.227	Cl	CH ₂ CHClCOOCH ₂ CH=CH ₂
.228	Cl	CH ₂ CHClCOOCH ₂ C ₆ H ₅
.229	Cl	CH ₂ CHClCOSCH ₃
.230	Cl	CH ₂ CHClCOSCH(CH ₃) ₂
.231	Cl	CH ₂ CHClCOSCH ₂ C ₆ H ₅
.232	Cl	CH ₂ CHClCONH ₂
.233	Cl	CH ₂ CHClCONH(CH ₂ CH=CH ₂)
.234	Cl	CH ₂ CHClCON(CH ₂ CH ₃) ₂
.235	Cl	CH ₂ CHClCONH(CH ₂ C ₆ H ₅)

Cmpd no.	R ₁	R ₃
.236	Cl	CH ₂ CHClCON(CH ₃)CH ₂ C ₆ H ₅
.237	Cl	CH=CHCOOH
.238	Cl	(E)-CH=CHCOOH
.239	Cl	(Z)-CH=CHCOOH
.240	Cl	CH=CHCOOCH ₃
.241	Cl	CH=CHCOOCH ₂ C ₆ H ₅
.242	Cl	CH=CHCOONH ₂
.243	Cl	CH=CHCONH(CH ₂ CH=CH ₂)
.244	Cl	CH=C(Cl)COOH
.245	Cl	CH=C(Cl)CONH ₂
.246	Cl	CH=C(Cl)CONH(CH ₂ CH ₃)
.247	Cl	CH=C(Cl)CON(CH ₂ CH ₃) ₂
.248	Cl	CH=C(Cl)CONH(CH ₂ C ₆ H ₅)
.249	Cl	CH=C(Cl)COSCH ₃
.250	Cl	CH=C(Cl)COSCH(CH ₃) ₂
.251	Cl	CH=C(CH ₃)COOH
.252	Cl	CH=C(CH ₃)CONH(CH ₂ CH=CH ₂)
.253	Cl	CH=C(CH ₃)CON(CH ₃) ₂
.254	Cl	CH=C(CH ₃)COSCH ₂ CH ₃
.255	Cl	CH=C(CN)COOH
.256	Cl	CH=C(CN)COOC(CH ₃) ₃
.257	Cl	CH=C(CN)CON(CH ₂ CH=CH ₂) ₂
.258	Cl	CH=C(COOH) ₂
.259	Cl	CH=C(C ₆ H ₅)COOH
.260	Cl	CH=CHCH ₂ OH
.261	H	CH ₂ OCOCH ₃
.262	H	COOH
.263	H	COCl
.264	H	COOCH ₃
.265	H	COOCH(CH ₃) ₂
.266	H	COOCH ₂ C ₆ H ₅
.267	H	COSCH(CH ₃) ₂
.268	H	CONH ₂
.269	H	CONHCH ₂ C ₆ H ₅
.270	H	CON(CH ₂ CH=CH ₂) ₂
.271	H	CON(CH ₃)OCH ₃
.272	H	COOCH(CH ₃)CH ₂ COOH

Cmpd no.	R ₁	R ₃
.273	H	COOCH(CH ₃)COOCH ₂ CH ₃
.274	H	COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.275	H	COOCH(CH ₃)CH ₂ COSCH ₂ CH ₃
.276	H	COOCH(CH ₃)CH ₂ CONH ₂
.277	H	COOCH(CH ₃)CH ₂ CONH(CH ₂ CH=CH ₂)
.278	H	COOCH(CH ₃)COOH
.279	H	COOC(CH ₃) ₂ COOH
.280	H	COOC(CH ₃) ₂ COOCH ₃
.281	H	COOC(CH ₃) ₂ COOCH(CH ₃) ₂
.282	H	COOC(CH ₃) ₂ COOCH ₂ CH ₃
.283	H	COOC(CH ₃) ₂ COOCH ₂ CH=CH ₂
.284	H	COOC(CH ₃) ₂ COOCH ₂ CH ₂ OCH ₂ CH ₃
.285	H	Cyclopropyl
.286	H	COOC(CH ₃) ₂ CON(CH ₃) ₂
.287	H	COOC(CH ₃) ₂ CONH(CH ₂ CH=CH ₂)
.288	H	COSCH(CH ₃)COOH
.289	H	CON(CH ₃)C(CH ₃) ₂ COOH
.290	H	CH ₃
.291	H	CH ₂ CH ₃
.292	H	CH(OH)CH ₃
.293	H	CH ₂ Cl
.294	H	CH ₂ OH
.295	H	CH ₂ OCOCH ₃
.296	H	CH=CHCF ₃
.297	H	CH ₂ CH ₂ CF ₃
.298	H	CH ₂ CH=CH ₂
.299	H	CH ₂ CHCICOOH
.300	H	CH ₂ CHCICOOCH ₂ CH ₃
.301	H	CH ₂ CHCICOOCH ₂ C ₆ H ₅
.302	H	CH ₂ CHCICOOCH ₂ CH=CH ₂
.303	H	CH ₂ CHCICOOOC(CH ₃) ₃
.304	H	CH ₂ CHCICOSCH(CH ₃) ₂
.305	H	CH ₂ CHCICONH ₂
.306	H	CH ₂ CHCICONH(CH ₂ CH ₃)
.307	H	CH ₂ CHCICON(CH ₃) ₂
.308	H	CH(Cl)CH(Cl)COOH
.309	H	CH ₂ C(CH ₃)CICOOH

Cmpd no.	R ₁	R ₃
.310	H	CH ₂ C(CH ₃)ClCOOCH ₂ CH ₃
.311	H	CH ₂ C(CH ₃)ClCOSCH ₃
.312	H	CH ₂ C(CH ₃)ClCONH(CH ₂ CH=CH ₂)
.313	H	Cyclopropyl
.314	H	CH=CHCOOH
.315	H	CH=C(CH ₃)COOH
.316	H	CH=C(Cl)COOH
.317	H	CH=C(CN)COOH
.318	H	CH=C(CN)COOCH ₂ CH=CH ₂
.319	H	CH=C(Cl)COOCH ₂ CH ₃
.320	H	CCCH ₃
.321	H	CH=C(Cl)COSCH ₂ CH ₃
.322	H	CH=C(Cl)CON(CH ₃) ₂
.323	CH ₃	CH ₂ OCOCH ₃
.324	CH ₃	COOH
.325	CH ₃	COCl
.326	CH ₃	COOCH ₃
.327	CH ₃	COOCH(CH ₃) ₂
.328	CH ₃	COOCH ₂ C ₆ H ₅
.329	CH ₃	COSCH(CH ₃) ₂
.330	CH ₃	CONH ₂
.331	CH ₃	CONHCH ₂ C ₆ H ₅
.332	CH ₃	CON(CH ₂ CH=CH ₂) ₂
.333	CH ₃	CON(CH ₃)OCH ₃
.334	CH ₃	COOCH(CH ₃)CH ₂ COOH
.335	F	CCH
.336	CH ₃	COOCH(CH ₃)CH ₂ COOCH ₂ CH=CH ₂
.337	CH ₃	COOCH(CH ₃)CH ₂ COSCH ₂ CH ₃
.338	CH ₃	COOCH(CH ₃)CH ₂ CONH ₂
.339	CH ₃	COOCH(CH ₃)CH ₂ CONH(CH ₂ CH=CH ₂)
.340	CH ₃	COOCH(CH ₃)COOH
.341	CH ₃	COOC(CH ₃) ₂ COOH
.342	CH ₃	COOC(CH ₃) ₂ COOCH ₃
.343	CH ₃	COOC(CH ₃) ₂ COOCH(CH ₃) ₂
.344	CH ₃	COOC(CH ₃) ₂ COOCH ₂ CH ₃
.345	CH ₃	COOC(CH ₃) ₂ COOCH ₂ CH=CH ₂
.346	CH ₃	COOC(CH ₃) ₂ COOCH ₂ CH ₂ OCH ₂ CH ₃


Cmpd no.	R ₁	R ₃
.347	CH ₃	COOC(CH ₃) ₂ CONH ₂
.348	CH ₃	COOC(CH ₃) ₂ CON(CH ₃) ₂
.349	CH ₃	COOC(CH ₃) ₂ CONH(CH ₂ CH=CH ₂)
.350	CH ₃	COSCH(CH ₃)COOH
.351	F	CCC(CH ₃) ₂ OH
.352	F	CF ₃
.353	CH ₃	CH ₂ CH ₃
.354	CH ₃	CH(OH)CH ₃
.355	CH ₃	CH ₂ Cl
.356	CH ₃	CH ₂ OH
.357	CH ₃	CH ₂ OCOCH ₃
.358	CH ₃	CH=CHCF ₃
.359	CH ₃	CH ₂ CH ₂ CF ₃
.360	CH ₃	CH ₂ CH=CH ₂
.361	CH ₃	CH ₂ CHClCOOH
.362	CH ₃	CH ₂ CHClCOOCH ₂ CH ₃
.363	CH ₃	CH ₂ CHClCOOCH ₂ C ₆ H ₅
.364	CH ₃	CH ₂ CHClCOOCH ₂ CH=CH ₂
.365	CH ₃	CH ₂ CHClCOOC(CH ₃) ₃
.366	CH ₃	CH ₂ CHClCOSCH(CH ₃) ₂
.367	CH ₃	CH ₂ CHClCONH ₂
.368	Cl	CCC(CH ₃) ₂ OCH ₃
.369	F	CCC(CH ₃) ₂ OCH ₃
.370	CH ₃	CH(Cl)CH(Cl)COOH
.371	CH ₃	CH ₂ C(CH ₃)ClCOOH
.372	CH ₃	CH ₂ C(CH ₃)ClCOOCH ₂ CH ₃
.373	CH ₃	CH ₂ C(CH ₃)ClCOSCH ₃
.374	CH ₃	CH ₂ C(CH ₃)ClCONH(CH ₂ CH=CH ₂)
.375	CH ₃	CH ₂ C(CH ₃)ClCON(CH ₃)(CH ₂ CH=CH ₂)
.376	CH ₃	CH=CHCOOH
.377	CH ₃	CH=C(CH ₃)COOH
.378	CH ₃	CH=C(Cl)COOH
.379	CH ₃	CH=C(CN)COOCH ₂ CH=CH ₂
.380	CH ₃	CH=C(CN)COOH
.381	CH ₃	CH=C(Cl)COOCH ₂ CH ₃
.382	CH ₃	CH=C(CH ₃)CONH(CH ₂ CH=CH ₂)
.383	CH ₃	CH=C(Cl)COSCH ₂ CH ₃

Cmpd no.	R ₁	R ₃
.384	CH ₃	CH=C(Cl)CON(CH ₃) ₂
.385	H	COOCH ₂ CH ₃
.386	CH ₃	COOCH ₂ CH ₃
.387	F	CH=CH ₂
.388	F	COSCH ₂ CH ₃
.389	F	COO ⁻ *NH ₂ (CH(CH ₃) ₂) ₂
.390	F	COO ⁻ *NH(CH ₂ CH ₂ OH) ₃
.391	F	COO ⁻ *K
.392	F	COOCH ₂ CH(CH ₃)CF ₃
.393	F	COOCH(CH ₃)COOCH ₂ CH ₃
.394	F	CON(CH ₂ CH ₂ CH ₃) ₂
.395	F	COOCH ₂ CH ₂ CH ₂ CH ₂ CH ₃
.396	F	COOCH ₂ CH ₂ SCH ₂ CH ₂ CH ₂ CH ₃
.397	F	COOCH ₂ CH ₂ CN
.398	F	COOCH ₂ CH ₂ SCH(CH ₃) ₂
.399	F	COOCH ₂ CH ₂ CH ₂ C ₆ H ₅
.400	F	COOCH(CH ₃)CH ₂ CH ₂ CH ₃
.401	F	COO(CH ₂) ₅ COOCH ₂ CH ₃
.402	F	COOC(CH ₃) ₃
.403	F	CH=C(CH ₃)COOCH ₂ CH ₃
.404	F	COO-cyclopropyl
.405	F	COO-cyclohexyl
.406	F	COOCH ₂ -cyclopropyl
.407	F	COOCH ₂ C ₆ H ₅
.408	F	COOCH ₂ CH ₂ OCH ₃
.409	F	COOCH ₂ CH ₂ CH ₃
.410	F	COOCH ₂ CH(CH ₃) ₂
.411	F	COOCH ₂ CH ₂ CH ₂ CH ₃
.412	F	COOCH ₂ CH(CH ₃)CH ₂ CH ₃
.413	F	COOCH ₂ (p-Cl-C ₆ H ₄)
.414	F	COOCH(CH ₃)C ₆ H ₅
.415	F	COSCH ₂ (o-F-C ₆ H ₄)
.416	F	COSCH(CH ₃)CH ₂ CH ₃
.417	F	COSCH(CH ₃)C ₆ H ₅
.418	F	COSCH ₂ CH ₂ CH ₃
.419	F	COSCH ₂ CH=CH ₂
.420	F	CON(CH ₂ CH=CH ₂)CH ₂ CH ₃

Cmpd no.	R ₁	R ₃
.421	F	CON(SO ₂ CH ₃)CH ₃
.422	F	CON(SO ₂ CH ₃)CH ₂ CH=CH ₂
.423	Cl	COO-cyclopropyl
.424	Cl	COO-cyclohexyl
.425	Cl	COOCH ₂ -cyclopropyl
.426	Cl	COOCH ₂ C ₆ H ₅
.427	Cl	COOCH ₂ CH ₂ OCH ₃
.428	Cl	COOCH ₂ CH ₂ CH ₃
.429	Cl	COOCH ₂ CH(CH ₃) ₂
.430	Cl	COOCH ₂ CH ₂ CH ₂ CH ₃
.431	Cl	COOCH ₂ CH(CH ₃)CH ₂ CH ₃
.432	Cl	COOCH ₂ (p-Cl-C ₆ H ₄)
.433	Cl	COOCH(CH ₃)C ₆ H ₅
.434	Cl	COOCH(CH ₃)C ₆ H ₅
.435	Cl	COSCH ₂ (o-F-C ₆ H ₄)
.436	Cl	COSCH(CH ₃)CH ₂ CH ₃
.437	Cl	COSCH(CH ₃)C ₆ H ₅
.438	Cl	COSCH ₂ CH ₂ CH ₃
.439	Cl	COSCH ₂ CH=CH ₂
.440	Cl	CON(CH ₂ CH=CH ₂)CH ₂ CH ₃
.441	Cl	CON(SO ₂ CH ₃)CH ₃
.442	Cl	CON(SO ₂ CH ₃)CH ₂ CH=CH ₂
.443	H	COOC(CH ₃) ₂ COCl
.444	F	CH=C(F)COOCH ₂ CH ₃ (E/Z)
.445	F	CH=C(Cl)COOCH ₂ CH ₃ (E/Z)
.446	F	Cl
.447	F	Br
.448	F	I


The intermediate products of formulae XXXIX and XXXX (e.g. in reaction scheme 12) are new and likewise comprise part of the invention. The following tables 600 to 647 exemplify preferred compounds of formulae XXXIX and XXXX.

Table 600: A preferred group of compounds of formula XXXIX corresponds to the general




defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₀.

Table 601: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₁.

Table 602: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₂.

Table 603: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₃.

Table 604: A further preferred group of compounds of formula XXXIX corresponds to the




R₁ and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₄.

Table 605: A further preferred group of compounds of formula XXXIX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₅.

Table 606: A further preferred group of compounds of formula XXXIX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₆.

Table 607: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₇.

Table 608: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₈.

Table 609: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₀₉.

Table 610: A further preferred group of compounds of formula XXXIX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₀.

Table 611: A further preferred group of compounds of formula XXXIX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₁.

Table 612: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₂.

Table 613: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₃.

Table 614: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₄.

Table 615: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₅.

Table 616: A further preferred group of compounds of formula XXXIX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₁₆.

Table 617: A preferred group of compounds of formula XXXX corresponds to the general




defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXX₆₁₇.

Table 618: A further preferred group of compounds of formula XXXX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₁₈.

Table 619: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₁₉.

Table 620: A further preferred group of compounds of formula XXXX corresponds to the




and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₀.

Table 621: A further preferred group of compounds of formula XXXX corresponds to the




R₁ and R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₁.

Table 622: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₂.

Table 623: A further preferred group of compounds of formula XXXX corresponds to the




are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₃.

Table 624: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₄.

Table 625: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₅.

Table 626: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₆.

Table 627: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₇.

Table 628: A further preferred group of compounds of formula XXXX corresponds to the




are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₈.

Table 629: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₂₉.

Table 630: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₀.

Table 631: A further preferred group of compounds of formula XXXIX corresponds to the




are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₃₁.

Table 632: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₂.

Table 633: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₃.

Table 634: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₄.

Table 635: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₅.

Table 636: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₆.

Table 637: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₇.

Table 638: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₈.

Table 639: A further preferred group of compounds of formula XXXX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₃₉.

Table 640: A further preferred group of compounds of formula XXXX corresponds to the




are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXX₆₄₀.

Table 641: A preferred group of compounds of formula XXXIX corresponds to the general




defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₁.

Table 642: A further preferred group of compounds of formula XXXIX corresponds to the




are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₂.

Table 643: A further preferred group of compounds of formula XXXIX corresponds to the




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₃.

Table 644: A further preferred group of compounds of formula XXXIX corresponds to the -




R₂ are defined in Table B, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₄.

Table 645: A further preferred group of compounds of formula I corresponds to the general




defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₅.

Table 646: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₆.

Table 647: A further preferred group of compounds of formula I corresponds to the general



defined in Table A, constituting the disclosure of 34 specific compounds of formula XXXIX₆₄₇

Table B

Cpmd no.	R ₁	R ₂
.001	F	Cl
.002	F	CN

Cpmd no.	R ₁	R ₂
.003	F	OCH ₃
.004	F	OCF ₃
.005	F	CF ₃
.006	F	Br
.007	F	NO ₂
.008	F	CH ₃
.010	F	OCH ₂ C≡CH
.011	Cl	CN
.012	Cl	OCH ₃
.013	Cl	OCF ₃
.014	Cl	CF ₃
.015	Cl	Br
.016	Cl	NO ₂
.017	Cl	CH ₃
.018	Cl	Cl
.019	Cl	CF ₂ H
.020	H	F
.021	H	Cl
.022	H	Br
.023	H	CF ₃
.024	H	OCF ₃
.025	H	NO ₂
.026	H	CN
.027	H	i-Pr
.028	F	C ₂ H ₅
.029	F	OCH ₂ CF ₃
.030	H	OCH ₂ CF ₃
.031	H	t-Bu
.032	F	t-Bu
.033	Cl	t-Bu
.034	H	J

Table C: Physicochemical data for prepared compounds from the above tables. The figure before the point indicates the number of the table, e.g. 1.004 means in Table 1 compound no. 004 of Table A and 634.001 means in Table 634 compound no. 001 of Table B.

Cmpd no.	physic. data
1.004	nD(40°C) 1.5159

1.038	$\alpha_D(20^\circ\text{C}) + 10.1^\circ$
1.352	m.p. 110-112°C
35.004	$^1\text{H-NMR}$ (CDCl_3): 8.11 ppm (s, 1H); 7.80 ppm (d, 1H); 7.35 ppm (s, 1H); 4.46 ppm (q, 2H); 1.41 ppm (t, 3H)
600.001	m.p. 133-134°C
608.001	m.p. 91-93°C
609.001	m.p. 114-116°C
617.001	m.p. 143-145°C
625.001	m.p. 140-143°C
626.001	m.p. 143-145°C
631.001	m.p. 154-157°C
634.001	m.p. 162-164°C

Examples of specific formulations for active ingredients of formula I, such as emulsifiable concentrates, solutions, wettable powders, coating granules, extruder granulates, dusts and suspension concentrates, are described in WO 97/34485 on pages 9–13.

Biological Examples

Example B1: Preemergence herbicidal action

Monocot and dicot test plants are sown in standard soil in plastic pots. Immediately after sowing, the plants are sprayed at a concentration of 2 kg active ingredient/ha with an aqueous suspension of the test compound prepared from a 25% wettable powder (Example F3, b)) according to WO 97/34485) or an emulsion of the test compound prepared from a 25% emulsifiable concentrate (Example F1 c)) according to WO 97/34485) (500 l of water/ha). The test plants are then cultivated in the greenhouse under optimum conditions. The test is evaluated 3 weeks later on a rating scale of 1–9 (1 = total damage, 9 = no action). Ratings of 1 to 4 (especially of 1 to 3) denote good to very good herbicidal action.

Test plants: *Lolium*, *Setaria*, *Sinapis*, *Solanum*, *Ipomea*.

The compounds of the invention show good herbicidal action.

An example of good herbicidal efficacy of compounds of formula I is given in Table B1.

Table B1: Pre-emergent action:

Test plant:	Lolium	Setaria	Sinapis	Solanum	Ipomea	Dose [g a.i./ha]
<u>Cmpd No.</u>						
1.004	2	1	1	1	1	2000
1.038	7	1	1	2	3	2000
1.352	1	1	1	1	1	2000

The same results are obtained by formulating the compounds of formula I in accordance with Examples F2 and F4 to F8 as described in WO 97/34485 .

Example B2: Post-emergent herbicidal action

In a greenhouse, monocot and dicot test plants are sown in standard soil in plastic pots and sprayed in the 4- to 6-leaf stage with an aqueous suspension of the test compounds of formula I prepared from a 25 % wettable powder (Example F3, b) according to WO 97/34485) or with an emulsion of the test compound prepared from a 25 % emulsifiable concentrate (Example F1 c)) according to WO 97/34485) at a concentration of 2 kg a.i./ha (500 l of water/ha). The test plants are then further cultivated in the greenhouse under optimum conditions. The test is evaluated about 18 days later on a rating scale of 1–9 (1 = total damage, 9 = no action). Ratings of 1 to 4 (especially of 1 to 3) denote good to very good herbicidal action. In this test the compounds of formula I exhibit a pronounced herbicidal action.

Test plants: Lolium, Setaria, Sinapis, Solanum, Ipomea.

In this test too the compounds of formula I exhibit a pronounced herbicidal action.

An example of good herbicidal efficacy of compounds of formula I is given in Table B2.

Table B2: Post-emergente action:

Test plant:	Lolium	Setaria	Sinapis	Solanum	Ipomea	Dose [g a.i./ha]
<u>Cmpd No.</u>						
1.004	1	1	1	1	1	2000
1.038	1	1	1	1	1	2000
1.352	1	1	1	1	1	2000

The same results are obtained by formulating the compounds of formula I in accordance with Examples F2 and F4 to F8 as described in WO 97/34485 .


The active ingredients of formula I can also be used for weed control by mixing with known herbicides as co-herbicides, for example as ready-for-use formulations or as tank mix. Suitable compounds for mixing with active ingredients of formula I are for example the following co-herbicides: compound of formula I + acetochlor; compound of formula I + acifluorfen; compound of formula I + aclonifen; compound of formula I + alachlor; compound of formula I + ametryn; compound of formula I + aminotriazol; compound of formula I + amidosulfuron; compound of formula I + asulam; compound of formula I + atrazine; compound of formula I + BAY FOE 5043; compound of formula I + benazolin; compound of formula I + bensulfuron; compound of formula I + bentazone; compound of formula I + bifenox; compound of formula I + bispyribac sodium; compound of formula I + bialaphos; compound of formula I + bromacil; compound of formula I + bromoxynil; compound of formula I + bromophenoxim; compound of formula I + butachlor; compound of formula I + butylate; compound of formula I + cafenstrole; compound of formula I + carbetamide; compound of formula I + chloridazone; compound of formula I + chlorimuron ethyl; compound of formula I + chlorbromuron; compound of formula I + chlorsulfuron; compound of formula I + chlortoluron; compound of formula I + cinosulfuron; compound of formula I + clethodim; compound of formula I + clodinafop; compound of formula I + clomazone; compound of formula I + clopyralid; compound of formula I + cloransulam; compound of formula I + cyanazine; compound of formula I + cyhalofop; compound of formula I + dalapon; compound of formula I + 2,4-D; compound of formula I + 2,4-DB; compound of formula I + desmetryn; compound of formula I + desmedipham; compound of formula I + dicamba; compound of formula I + diclofop; compound of formula I + difenzoquat methyl sulfate; compound of formula I + diflufenican; compound of formula I + dimefuron; compound of formula I + dimepiperate; compound of formula I + dimethachlor; compound of formula I + dimethametryn; compound of formula I + dimethenamid; compound of formula I + S-dimethenamid; compound of formula I + dinitramine; compound of formula I + dinoterb; compound of formula I + dipropetryn; compound of formula I + diuron; compound of formula I + diquat; compound of formula I + DSMA; compound of formula I + EPTC; compound of formula I + esprocarb; compound of formula I + ethalfluralin; compound of formula I + ethametsulfuron; compound of formula I + ethephon; compound of formula I + ethofumesate; compound of formula I + ethoxysulfuron; compound of formula I + fencloirim; compound of formula I + flamprop; compound of formula I + fluazasulfuron; compound of formula I + fluazifop; compound of formula I + flumetralin; compound of formula I + flumetsulam; compound of formula I + fluometuron; compound of formula I + flurchloridone; compound of formula I + fluoxaprop; compound of formula I + fluroxypyr; compound of formula I + fluthiacet-methyl; compound of formula I + fluxofenim;

compound of formula I + fomesafen; compound of formula I + glufosinate; compound of formula I + glyphosate; compound of formula I + halosulfuron; compound of formula I + haloxyfop; compound of formula I + hexazinone; compound of formula I + imazamethabenz; compound of formula I + imazapyr; compound of formula I + imazaquin; compound of formula I + imazethapyr; compound of formula I + imazosulfuron; compound of formula I + ioxynil; compound of formula I + isoproturon; compound of formula I + isoxaben; compound of formula I + isoxaflutole; compound of formula I + karbutylate; compound of formula I + lactofen; compound of formula I + lenacil; compound of formula I + linuron; compound of formula I + MCPP; compound of formula I + metamitron; compound of formula I + metazachlor; compound of formula I + methabenzthiazuron; compound of formula I + methazole; compound of formula I + metobromuron; compound of formula I + metolachlor; compound of formula I + S-metolachlor; compound of formula I + metosulam; compound of formula I + metribuzin; compound of formula I + metsulfuron methyl; compound of formula I + molinate; compound of formula I + MCPA; compound of formula I + MSMA; compound of formula I + napropamide; compound of formula I + NDA-402989; compound of formula I + n; compound of formula I + nicosulfuron; compound of formula I + norflurazon; compound of formula I + oryzalin; compound of formula I + oxadiazon; compound of formula I + oxasulfuron; compound of formula I + oxyfluorfen; compound of formula I + paraquat; compound of formula I + pendimethalin; compound of formula I + phenmedipham; compound of formula I + phenoxaprop-P-ethyl (R); compound of formula I + picloram; compound of formula I + pretilachlor; compound of formula I + primisulfuron; compound of formula I + prometon; compound of formula I + prometryn; compound of formula I + propachlor; compound of formula I + propanil; compound of formula I + propazine; compound of formula I + propaquizafop; compound of formula I + propyzamide; compound of formula I + prosulfuron; compound of formula I + pyrazolynate; compound of formula I + pyrazosulfuron ethyl; compound of formula I + pyrazoxyphen; compound of formula I + pyridate; compound of formula I + pyriminobac methyl; compound of formula I + pyriothiobac sodium; compound of formula I + quinclorac; compound of formula I + quizalofop; compound of formula I + rimsulfuron; compound of formula I + sequestren; compound of formula I + sethoxydim; compound of formula I + simetryn; compound of formula I + simazin; compound of formula I + sulcotrione; compound of formula I + sulfosate; compound of formula I + sulfosulfuron methyl; compound of formula I + tebutam; compound of formula I + tebuthiuron; compound of formula I + terbacil; compound of formula I + terbumeton; compound of formula I + terbuthylazin; compound of formula I + terbutryn; compound of formula I + thiazafluron; compound of formula I + thiazopyr; compound of formula I + thifensulfuron methyl; compound of formula I + thiobencarb; compound of

formula I + tralkoxydim; compound of formula I + triallate; compound of formula I + triasulfuron; compound of formula I + trifluralin; compound of formula I + tribenuron methyl; compound of formula I + triclopyr; compound of formula I + triflusulfuron; compound of formula I + trinexapac ethyl, as well as esters and salts of these compounds for mixing with a compound of formula I, which named for example in The Pesticide Manual, Eleventh Edition, 1997, BCPC.

What is claimed is:

1. Compounds of formula I



wherein

A is =N- or $\text{=}\overset{+}{\text{N}}\text{-O}^-$;

R₁ is hydrogen, fluorine, chlorine, bromine or methyl;

R₂ is C₁-C₄alkyl, C₁-C₄halogenalkyl, halogen, hydroxy, C₁-C₄alkoxy, C₁-C₄halogenalkoxy, nitro, amino or cyano;

R₃ is cyano or R₄C(O)-;

R₄ is hydrogen, fluorine, chlorine, C₁-C₈alkyl, C₂-C₈alkenyl, C₂-C₈alkinyl, C₃-C₆cycloalkyl, C₁-C₈halogenalkyl, cyano-C₁-C₄alkyl, C₂-C₈halogenalkenyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl or benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl; or

R₃ is R₅X₁C(O)-;

X₁ is oxygen, sulfur, $\text{R}_6\text{-N-}$ or $\text{R}_7\text{-O-N-}$;

R₅ is hydrogen, C₁-C₈alkyl, C₃-C₈alkenyl, C₃-C₈alkinyl, C₃-C₆cycloalkyl, C₃-C₆cycloalkyl-C₁-C₆alkyl, C₁-C₈halogenalkyl, C₃-C₈halogenalkenyl, cyano-C₁-C₄alkyl, C₁-C₄alkoxy-C₁-C₄alkyl, C₃-C₆alkenyloxy-C₁-C₄alkyl, (oxiranyl)-CH₂-, oxetanyl-, C₁-C₄alkylthio-C₁-C₄alkyl, phenyl, phenyl substituted once to three times by halogen, C₁-C₄alkyl or C₁-C₄halogenalkyl, benzyl or benzyl substituted once to three times on the phenyl ring by halogen, C₁-C₄alkyl or C₁-C₄-

halogenalkyl, phenyl-C₂-C₆alkyl, C₁-C₆alkyl-CO-C₁-C₄alkyl, $\text{C}_1\text{-C}_6\text{-Alkyl-C(O)-[C}_1\text{-C}_4\text{-alkylen]-}$
 $\text{(C}_6\text{H}_5\text{)}$

$\text{R}_8\text{X}_2\text{C(O)-C}_1\text{-C}_6\text{-alkyl,}$ $\text{R}_8\text{X}_2\text{C(O)-[C}_1\text{-C}_6\text{-alkylen]-}$
 $\text{(C}_6\text{H}_5\text{)}$ or $\text{R}_8\text{X}_2\text{C(O)-C}_3\text{-C}_6\text{cycloalkyl;}$

X_2 is oxygen, sulfur, $\begin{array}{c} R_9-N- \\ | \end{array}$ or $\begin{array}{c} R_{10}-O-N- \\ | \end{array}$;

R_8 is hydrogen, C_1 - C_8 alkyl, C_3 - C_8 alkenyl, C_3 - C_8 alkinyl, C_3 - C_6 cycloalkyl, C_1 - C_8 halogenalkyl, C_3 - C_8 halogenalkenyl, cyano- C_1 - C_4 alkyl, C_1 - C_4 alkoxy- C_1 - C_4 alkyl, C_3 - C_6 alkenyloxy- C_1 - C_4 alkyl, (oxiranyl)- CH_2 -, oxetanyl, C_1 - C_4 alkylthio- C_1 - C_4 alkyl, phenyl, phenyl substituted once to three times by halogen, C_1 - C_4 alkyl or C_1 - C_4 halogenalkyl, benzyl, benzyl substituted once to three times on the phenyl ring by halogen, C_1 - C_4 alkyl or C_1 - C_4 halogenalkyl, or phenyl- C_2 - C_6 alkyl;

R_6 , R_7 , R_9 and R_{10} are independently of one another hydrogen, C_1 - C_8 alkyl, C_3 - C_8 alkenyl, C_3 - C_8 alkinyl, C_1 - C_8 halogenalkyl or benzyl; or

R_3 is B_1 - C_1 - C_8 alkyl, B_1 - C_2 - C_8 alkenyl, B_1 - C_2 - C_8 alkinyl, B_1 - C_1 - C_8 halogenalkyl, B_1 - C_2 - C_8 halogenalkenyl, B_1 - C_1 - C_4 alkoxy- C_1 - C_4 alkyl, B_1 - C_1 - C_4 alkylthio- C_1 - C_4 alkyl or B_1 - C_3 - C_6 cycloalkyl;

B_1 is hydrogen, cyano, hydroxy, C_1 - C_8 alkoxy, C_3 - C_6 alkenyloxy, $R_{11}X_3C(O)-$, C_1 - C_4 alkylcarbonyl or C_1 - C_4 halogenalkylcarbonyl ;

X_3 has the same meaning as X_2 ;

R_{11} has the same meaning as R_8 ; or


R_3 is $B_2-C(R_{12})=CH-$;

B_2 is nitro, cyano or $R_{13}X_4C(O)-$;

R_{12} is cyano or $R_{14}X_5C(O)-$;

X_4 and X_5 have the same meaning as X_2 ; and

R_{13} and R_{14} have the same meaning as R_8 ;



R₁₅ is C₁-C₃alkyl, C₁-C₃halogenalkyl or amino;

R₁₆ is C₁-C₃halogenalkyl, C₁-C₃alkyl-S(O)_{n1}, C₁-C₃halogenalkyl-S(O)_{n1} or cyano; or

R₁₆ and R₁₅ together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

n₁ is 0, 1 or 2;

R₁₇ is hydrogen, C₁-C₃alkyl, halogen, C₁-C₃halogenalkyl or cyano; or

R₁₇ and R₁₆ together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R₁₈ is hydrogen, C₁-C₃alkyl, halogen or cyano;

R₁₉ is C₁-C₃halogenalkyl; or

R₁₉ and R₁₈ together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R₂₀ is hydrogen or C₁-C₃alkyl or halogen; or

R₂₀ and R₁₉ together form a C₃- or C₄alkylene or C₃- or C₄alkenylene bridge which may be substituted by halogen, C₁-C₃halogenalkyl or cyano;

R₂₁ is hydrogen, C₁-C₃alkyl, halogen, C₁-C₃halogenalkyl, R₄₀O-, R₄₁S(O)_{n2}, R₄₂(R₄₃)N,

R₄₅(R₄₆)N-C(R₄₄)=N-, hydroxy, nitro or N≡C-S- ;

R₄₀ is C₁-C₃alkyl, C₁-C₃halogenalkyl, C₂-C₄alkenyl, C₃- or C₄alkinyl or C₁-C₅alkoxycarbonyl-C₁-C₄alkyl;

R₄₁ is C₁-C₄alkyl or C₁-C₄halogenalkyl;

n₂ is 0, 1 or 2;

R₄₂ is hydrogen, C₁-C₄alkyl, C₁-C₄halogenalkyl, C₃-C₆cycloalkyl, OHC- or C₁-C₄alkylcarbonyl;

R₄₃, R₄₄, and R₄₆ are independently of one another hydrogen or C₁-C₄alkyl;

R₄₅ is C₁-C₄alkyl;

R₂₂ is hydrogen, C₁-C₄alkyl, halogen, C₁-C₄halogenalkyl, C₂-C₄alkenyl, C₃-C₅halogenalkenyl, C₃- or C₄alkinyl, C₁-C₄alkoxy, C₁-C₄alkylcarbonyl, C₁-C₄halogenalkylcarbonyl, C₂-C₄alkenylcarbonyl, C₂-C₄halogenalkenylcarbonyl, C₂-C₄alkinylcarbonyl, C₂-C₄halogenalkinylcarbonyl, C₁-C₄alkylcarbamoyl, C₁-C₄alkylS(O)_{n3}, C₃- or C₄alkinylS(O)_{n3}, OHC-, nitro, amino, cyano or N≡C-S- ;

n₃ is 0, 1 or 2;

R₂₃ and R₂₄ are independently of one another hydrogen, C₁-C₄alkyl, halogen, C₁-C₄halogenalkyl or cyano;

R₂₅ and R₂₆ are independently of one another hydrogen, methyl, halogen, hydroxy or =O;

R₂₇ and R₂₈ are independently of one another hydrogen, C₁-C₄alkyl or C₁-C₄halogenalkyl;

R₂₉ and R₃₀ are independently of one another hydrogen, C₁-C₃alkyl or halogen;

R₃₁ and R₃₂ are independently of one another hydrogen or C₁-C₄alkyl; or

R₃₁ and R₃₂ together form the group $\begin{array}{c} \text{R}_{47} \\ \diagup \\ \text{C} \\ \diagdown \\ \text{R}_{48} \end{array}$;

R₄₇ and R₄₈ are independently of one another C₁-C₄alkyl; or

R₄₇ and R₄₈ together form a C₄ or C₅alkylene bridge;

R₃₃ is hydrogen or C₁-C₃alkyl; or

R₃₃ together with R₃₂ forms a C₃-C₅alkylene bridge which may be broken by oxygen and/or substituted by halogen, C₁-C₄alkyl, C₂-C₄alkenyl, C₁-C₃alkylcarbonyloxy, C₁-C₃alkylsulfonyloxy, hydroxy or =O;

R₃₄, R₃₅, R₃₆ and R₃₇ are independently of one another hydrogen, C₁-C₃alkyl, C₃- or C₄alkenyl or C₃-C₅alkinyl; or

R₃₄ and R₃₅ on the one hand and R₃₆ and R₃₇ on the other each form a C₂-C₅alkylene or C₃-C₅alkenylene bridge together, which may be broken by oxygen, -C(O)-, sulfur, or -S(O)₂- ;

R₃₈ is hydrogen, C₁-C₄alkyl, C₁-C₄halogenalkyl, C₃- or C₄alkenyl or C₃- or C₄alkinyl;


R₃₉ is hydrogen, C₁-C₄alkyl, C₁-C₃alkoxy-C₁- or -C₂alkyl, C₁-C₄halogenalkyl, C₃- or C₄alkenyl, C₃- or C₄halogenalkenyl or C₃- or C₄alkinyl; or

R₃₉ and R₃₈ together form a C₃-C₅alkylene bridge; and


$X_6, X_7, X_8, X_9, X_{10}, X_{11}, X_{12}, X_{13}, X_{14}, X_{15}, X_{16}, X_{17}, X_{18}$ and X_{19} are independently of one another oxygen or sulfur,
and the agrochemically acceptable salts and stereoisomers of these compounds of formula I

2. Compounds of formula I of claim 1, wherein R_2 is methyl, halogen, hydroxy, nitro, amino or cyano.

3. A method for the preparation of compounds of formula I,



wherein R_1, R_2, R_3, A and W are as defined in claim 1, comprising treating a compound of formula II




wherein R_1, R_2 and W have the meanings indicated, and L_4 is a leaving group, either
a) in a suitable solvent, where appropriate in the presence of a base, a catalyst and a compound of formula V



wherein R_5 is hydrogen or C_1 - C_4 alkyl, under positive pressure with carbon monoxide, or
b) in a suitable solvent in the presence of a tertiary amine, a catalyst, and an olefin by means of the Heck reaction, or under said conditions by means of reaction with a Grignard reagent of formula Va




wherein R_3 is B_1 - C_1 - C_8 alkyl, B_1 - C_2 - C_8 alkenyl, B_1 - C_2 - C_8 alkinyl, B_1 - C_1 - C_8 halogenalkyl, B_1 - C_2 - C_8 halogenalkenyl, B_1 - C_1 - C_4 alkoxy- C_1 - C_4 alkyl, B_1 - C_1 - C_4 alkylthio- C_1 - C_4 alkyl or B_1 - C_3 - C_6 cycloalkyl and B_1 has the meaning defined in claim I, or in an inert solvent and in the presence of a catalyst with a tin compound of formula Vb




wherein R_3 has the meaning indicated, or

- c) where applicable in an inert solvent at reaction temperatures of 20–300°C subjecting said compound to a cyanidation reaction, or
 d) first oxidizing said compound in a suitable solvent to form a compound of formula IV




and treating this in an inert solvent with dimethylcarbamoyl chloride and a cyanidation reagent, and then where applicable further functionalizing the compound according to the definitions of A and R₃.

4. Compounds of formula II



wherein R₁ and R₂ are as defined in claim 1, W is a W₃, W₄, W₅, W₆, W₉ or W₁₀ group and L₄ is a leaving group.

5. A herbicidal and plant growth inhibiting composition, which comprises a herbicidally effective amount of the compound of formula I on an inert carrier.
6. A herbicidal and plant growth inhibiting composition of claim 5 comprising as an additional component a further co-herbicide.
7. A method of controlling undesirable plant growth, which comprises treating the plants or the locus thereof with a herbicidally effective amount of a compound of formula I or of a composition containing such a compound.
8. Use of a composition according to claim 5 for controlling undesirable plant growth.





INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 401/04, 471/04, 487/04, A01N 43/653, 43/50, 43/52, 43/54, 43/56</p>	A3	<p>(11) International Publication Number: WO 99/55693</p> <p>(43) International Publication Date: 4 November 1999 (04.11.99)</p>		
<table style="width: 100%; border: none;"> <tr> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(21) International Application Number: PCT/EP99/02815</p> <p>(22) International Filing Date: 26 April 1999 (26.04.99)</p> <p>(30) Priority Data: 959/98 28 April 1998 (28.04.98) CH</p> <p>(71) Applicant (for all designated States except AT US): NOVAR-TIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).</p> <p>(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KUNZ, Walter [CH/CH]; Buchenstrasse 9, CH-4104 Oberwil (CH). NEBEL, Kurt [CH/CH]; Baselweg 32, CH-4146 Hochwald (CH).</p> <p>(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).</p> </td> <td style="width: 50%; vertical-align: top; padding: 5px;"> <p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 16 December 1999 (16.12.99)</p> </td> </tr> </table>			<p>(21) International Application Number: PCT/EP99/02815</p> <p>(22) International Filing Date: 26 April 1999 (26.04.99)</p> <p>(30) Priority Data: 959/98 28 April 1998 (28.04.98) CH</p> <p>(71) Applicant (for all designated States except AT US): NOVAR-TIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).</p> <p>(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KUNZ, Walter [CH/CH]; Buchenstrasse 9, CH-4104 Oberwil (CH). NEBEL, Kurt [CH/CH]; Baselweg 32, CH-4146 Hochwald (CH).</p> <p>(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 16 December 1999 (16.12.99)</p>
<p>(21) International Application Number: PCT/EP99/02815</p> <p>(22) International Filing Date: 26 April 1999 (26.04.99)</p> <p>(30) Priority Data: 959/98 28 April 1998 (28.04.98) CH</p> <p>(71) Applicant (for all designated States except AT US): NOVAR-TIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).</p> <p>(71) Applicant (for AT only): NOVARTIS-ERFINDUNGEN VERWALTUNGSGESELLSCHAFT MBH [AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): KUNZ, Walter [CH/CH]; Buchenstrasse 9, CH-4104 Oberwil (CH). NEBEL, Kurt [CH/CH]; Baselweg 32, CH-4146 Hochwald (CH).</p> <p>(74) Agent: BECKER, Konrad; Novartis AG, Corporate Intellectual Property, Patent & Trademark Dept., CH-4002 Basel (CH).</p>	<p>(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> <p>(88) Date of publication of the international search report: 16 December 1999 (16.12.99)</p>			
<p>(54) Title: N-HETEROARYL-SUBSTITUTED PYRIDINE DERIVATIVES AND THEIR USE AS HERBICIDES</p> <div style="text-align: center; margin: 20px 0;"> (I) (a) (W1) </div> <div style="display: flex; flex-wrap: wrap; justify-content: space-around;"> <div style="text-align: center; margin: 10px;"> (W2) </div> <div style="text-align: center; margin: 10px;"> (W3) </div> <div style="text-align: center; margin: 10px;"> (W4) </div> <div style="text-align: center; margin: 10px;"> (W5) </div> <div style="text-align: center; margin: 10px;"> (W6) </div> <div style="text-align: center; margin: 10px;"> (W7) </div> <div style="text-align: center; margin: 10px;"> (W8) </div> <div style="text-align: center; margin: 10px;"> (W9) </div> <div style="text-align: center; margin: 10px;"> (W10) </div> </div>				
<p>(57) Abstract</p> <p>Compounds of formula (I), wherein A = N- or (a); R₁ is hydrogen, fluorine, chlorine, bromine or methyl; R₂ is C₁-C₄alkyl, C₁-C₄halogenalkyl, halogen, hydroxy, C₁-C₄alkoxy, C₁-C₄halogenalkoxy, nitro, amino or cyano; W is a (W1), (W2), (W3), (W4), (W5), (W6), (W7), (W8), (W9) or (W10) group; and R₃, R₁₅ to R₃₉ and X₆ to X₁₉ are as defined in claim 1, and the agrochemically acceptable salts and stereoisomers of these compounds of formula (I) are suitable for use as herbicides.</p>				

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 99/02815

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D401/04 C07D471/04 C07D487/04 A01N43/653 A01N43/50
 A01N43/52 A01N43/54 A01N43/56

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ²	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 97 02243 A (BAYER AKTIENGESSELLSCHAFT) 23 January 1997 (1997-01-23) the whole document ---	1,6
Y	WO 93 18008 A (JAMES, DONALD, R. ET AL.) 16 September 1993 (1993-09-16) the whole document ---	1,6
Y	WO 92 16510 A (CIBA-GEIGY AG) 1 October 1992 (1992-10-01) the whole document ---	1,6
Y	DE 195 30 606 A (BASF AG) 27 February 1997 (1997-02-27) cited in the application the whole document --- -/--	1,6

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.³ Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

15 October 1999

Date of mailing of the international search report

27/10/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Kyriakakou, G

INTERNATIONAL SEARCH REPORT

International Application No

PL./EP 99/02815

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	EP 0 370 332 A (BAYER AG) 30 May 1990 (1990-05-30) cited in the application the whole document ----	1,6
Y	DE 39 17 469 A (BAYER AG) 6 December 1990 (1990-12-06) cited in the application the whole document ----	1,6
Y	US 4 406 689 A (RICHARD J. ANDERSON ET AL.) 27 September 1983 (1983-09-27) cited in the application the whole document ----	1,6
Y	WO 92 00976 A (SANKYO COMPANY) 23 January 1992 (1992-01-23) cited in the application abstract ----	1,6
Y	US 5 250 504 A (LESTER L. MARAVETZ ET AL.) 5 October 1993 (1993-10-05) cited in the application the whole document -----	1,6

INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 99/02815

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: 1-8
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02815

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9702243 A	23-01-1997	DE 19603332 A	02-01-1997
		AU 707357 B	08-07-1999
		AU 6356196 A	05-02-1997
		BR 9609301 A	25-05-1999
		CA 2225830 A	23-01-1997
		CN 1193960 A	23-09-1997
		EP 0835243 A	15-04-1998
		HU 9802279 A	28-01-1999
WO 9318008 A	16-09-1993	US 5444038 A	22-08-1995
		AU 665818 B	18-01-1996
		CN 1079961 A	29-12-1993
		EP 0630367 A	28-12-1994
		HU 70876 A	28-11-1995
		IL 104977 A	04-01-1998
		JP 7508259 T	14-09-1995
		MX 9301301 A	29-04-1994
		TR 27754 A	11-07-1995
		US 5928998 A	27-07-1995
		ZA 9301632 A	05-08-1994
WO 9216510 A	01-10-1992	AT 139768 T	15-07-1996
		AU 672578 B	10-10-1996
		AU 1343192 A	21-10-1992
		BR 9205752 A	08-11-1994
		CA 2106302 A	20-09-1992
		CN 1064862 A	30-09-1992
		DE 69211841 D	01-08-1996
		DK 577629 T	29-07-1996
		EG 20108 A	31-07-1997
		EP 0577629 A	12-01-1994
		ES 2089506 T	01-10-1996
		GR 3020400 T	30-09-1996
		HR 950136 A	31-08-1997
		IE 72957 B	07-05-1997
		JP 6506201 T	14-07-1994
		MD 960225 A	30-11-1997
		NZ 241996 A	25-11-1994
		SI 9210249 A	30-04-1995
		TR 25475 A	01-05-1993
		US 5506193 A	09-04-1996
		US 5494890 A	27-02-1996
DE 19530606 A	27-02-1997	AU 6742996 A	12-03-1997
		CA 2226765 A	27-02-1997
		WO 9707114 A	27-02-1997
		EP 0846113 A	10-06-1998
EP 370332 A	30-05-1990	DE 3839480 A	31-05-1990
		DD 297963 A	30-01-1992
		DE 58907343 D	05-05-1994
		JP 2184675 A	19-07-1990
		JP 2735905 B	02-04-1998
		US 5006148 A	09-04-1991
		US 5554580 A	10-09-1996
DE 3917469 A	06-12-1990	NONE	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 99/02815

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
US 4406689	A	27-09-1983	US 4406690 A	27-09-1983
WO 9200976	A	23-01-1992	JP 4352782 A	07-12-1992
US 5250504	A	05-10-1993	US 5198014 A	30-03-1993

This Page Blank (uspto)